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Abstract
Background: Soil transmitted (or intestinal) helminths and schistosomes affect
millions of children worldwide.
Objectives: To use individual participant data network meta‐analysis (NMA) to
explore the effects of different types and frequency of deworming drugs on anaemia,
cognition and growth across potential effect modifiers.
Search Methods: We developed a search strategy with an information scientist to
search MEDLINE, CINAHL, LILACS, Embase, the Cochrane Library, Econlit, Internet
Documents in Economics Access Service (IDEAS), Public Affairs Information Service
(PAIS), Social Services Abstracts, Global Health CABI and CAB Abstracts up to March
27, 2018. We also searched grey literature, websites, contacted authors and screened
references of relevant systematic reviews.
Selection Criteria:We included randomised and quasirandomised deworming trials in
children for deworming compared to placebo or other interventions with data on
baseline infection.
Data Collection and Analysis: We conducted NMA with individual participant data
(IPD), using a frequentist approach for random‐effects NMA. The covariates were:
age, sex, weight, height, haemoglobin and infection intensity. The effect estimate
chosen was the mean difference for the continuous outcome of interest.
Results: We received data from 19 randomized controlled trials with 31,945 participants.
Overall risk of bias was low. There were no statistically significant subgroup effects across
any of the potential effect modifiers. However, analyses showed that there may be greater
effects on weight for moderate to heavily infected children (very low certainty evidence).
Authors’ Conclusions: This analysis reinforces the case against mass deworming at a
population‐level, finding little effect on nutritional status or cognition. However,
children with heavier intensity infections may benefit more. We urge the global
community to adopt calls to make data available in open repositories to facilitate IPD
analyses such as this, which aim to assess effects for the most vulnerable individuals.
1 | PLAIN LANGUAGE SUMMARY
Mass deworming programmes have little effect on nutritional status
and cognitive development on a population level
1.1 | The Campbell review in brief
The effectiveness and cost‐effectiveness of mass deworming of
children to improve child health and other outcomes is debated. This
independent analysis reinforces the case against mass deworming at
a population‐level, finding little effect on nutritional status or
cognition. However, children with heavier intensity infections may
benefit more.
1.2 | What is this review about?
Soil‐transmitted helminthiasis (STH) and schistosomiasis affects over
800 million people. There is ongoing debate about whether mass
deworming of children improves child nutritional status and cognitive
development in endemic areas.
1.2.1 | What studies are included?
Randomised trials of mass deworming for STH (alone or in combination
with other drugs or child health interventions) for children aged 6 months
to 16 years were eligible if they reported at least one of the following
outcomes: growth, haemoglobin, serum ferritin, or cognitive processing or
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development. Trials had to collect data on baseline STH infection
intensity, since the main purpose of this review was to assess effect
modification across intensity of infection.
Individual participant data (IPD) was obtained from 19 out of 41
eligible randomised trials. These 19 trials included 31,945 partici-
pants and had an overall low risk of bias.
A secondary analysis added new data to the meta‐analysis of STH
deworming versus placebo of a previous Campbell review by the same
authors. This analysis included 29 randomised trials, with data from two
studies which had not published weight gain data and updated effect
estimates from three studies based on the data provided by authors.
These studies were conducted in 11 low and middle income
countries. Most programmes conducted deworming every 4 months or
more frequently. Seven out of 19 studies gave a single dose of
deworming. Children were school‐age, with a median of 11 years of age.
1.3 | Does deworming improve child health and
other welfare outcomes?
Mass deworming for STHs compared to placebo probably has little to
no effect on nutritional status or cognitive development (moderate
certainty evidence). Children with moderate to heavy intensity
infections of Ascaris lumbricoides or Trichuris trichiuria may experience
greater weight gain (very low certainty evidence). No other differences
in effects were found across age, sex or baseline nutritional status.
Findings are consistent for studies at low risk of bias and for
other methodological considerations such as completer analyses.
There was no trend in effect according to publication year, baseline
A. lumbricoides prevalence or T. trichuria prevalence in the full dataset
of 29 studies. Higher baseline hookworm prevalence was weakly
associated with greater effects of STH deworming.
1.4 | What are the implications of this review for
policy makers and decision makers?
This analysis replicates the prior findings of small effects of mass
deworming at the population level. In areas where there are children
with moderate to heavy intensity infections, which are increasingly
uncommon, mass deworming may be beneficial, but this analysis was
limited by the small number of children with heavy intensity infections
in this sample (<1,000). In areas with light intensity infections, mass
deworming programmes probably have very small effects on weight
for these children and additional policy options need to be explored to
improve child health and nutrition in these areas.
1.5 | What are the research implications of this
review?
This analysis was severely limited by not being able to obtain IPD for
many older studies, which may have included children with heavier
intensity infections. Greater adoption of calls for open, structured
data from trials could maximise the benefit of research to understand
effects in the most vulnerable and marginalised populations within
these trials.
Summary of findings table 1: Deworming with any STH drug
compared to placebo for children in STH endemic areas
Deworming with any STH drug compared to placebo for children in STH endemic areas
Patient or population: Children
Settings: STH endemic areas
Intervention: Deworming with any STH drug
Comparison: Placebo
Time: 4 months or longer
Direct evidence Network meta‐analysis
Outcomes
No. of participants
(studies) MD (95% CI)
Quality of the
evidence (GRADE) MD (95% CI)
Quality of the
evidence (GRADE)
Weight (change in kg) 11,024 (9 studies) 0.05 (−0.02, 0.11) ⊕⊕⊕⊝ moderatea 0.01 (−0.08,0.11) ⊕⊕⊕⊝ moderatea
Height (change in cm) 11,024 (9 studies) 0.04 (−0.04, 0.11) ⊕⊕⊕⊝ moderatea 0.09 (−0.08,0.27) ⊕⊕⊕⊝ moderatea
Hemoglobin (change in g/L) 11,024 (9 studies) 0.23 (−0.52, 0.97) ⊕⊕⊕⊝ moderatea 0.32 (−0.63,1.26) ⊕⊕⊝⊝ lowa,b
Cognition 6 studies (5,814
participants)
There was little to no effect on cognitive outcomes measured on various scales for short‐term
attention, school achievement, developmental scales
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Note: Findings based on the analysis of main effects of 19 studies providing individual participant data.
Abbreviations: CI, confidence interval; IPD, individual participant data; STH, soil transmitted helminth.
aDowngraded for study limitations—obtained only a selected sample of IPD from 19 out of 41 eligible studies.
bDowngraded for imprecision.
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Deworming with Praziquantel alone or in combination with any STH deworming compared to placebo for children in STH endemic areas
Patient or population: Children
Settings: STH endemic areas
Intervention: Deworming with any STH drug and Praziquantel
Comparison: Placebo
Time: 4 months or longer
Direct evidence Network meta‐analysis
Outcomes
No. of participants
(studies) MD (95% CI)
Quality of the
evidence (GRADE) MD (95% CI)
Quality of the
evidence (GRADE)
Weight (change in kg) 2,171 (5 studies) 0.04 (−0.12, 0.20) ⊕⊕⊕⊝ moderatea 0.04 (−0.11, 0.19) ⊕⊕⊕⊝ moderatea
Height (change in cm) 2,171 (5 studies) −0.10 (−0.44, 0.25) ⊕⊕⊕⊝ moderatea −0.06 (−0.31, 0.18) ⊕⊕⊕⊝ moderatea
Hemoglobin (change in
g/L)
2,171 (5 studies) 2.02 (0.93, 3.11) ⊕⊕⊕⊝ moderatea 1.85 (0.53, 3.18) ⊕⊕⊝⊝ lowa,b
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Note: Findings based on the analysis of main effects of 19 studies providing individual participant data.
Abbreviations: CI, confidence interval; STH, soil transmitted helminth.
aDowngraded for study limitations—obtained only a selected sample of IPD from 19 out of 41 eligible studies.
bDowngraded for imprecision.
Mass deworming with any STH drug with iron or micronutrients compared to placebo for children in STH endemic areas
Patient or population: Children
Settings: STH endemic areas
Intervention: Mass deworming with any STH drug combined with iron or micronutritents
Comparison: Placebo
Time: 4 months or longer
Direct evidence Network meta‐analysis
Outcomes
No. of participants
(studies) MD (95% CI)
Quality of the
evidence (GRADE) MD (95% CI)
Quality of the
evidence (GRADE)
Weight (change in kg) 3,851 (5 studies) 0.00 (−0.07, 0.08) ⊕⊕⊕⊝ moderatea −0.02 (−0.15,0.12) ⊕⊕⊕⊝ moderatea
Height (change in cm) 3,851 (5 studies) 0.02 (−0.07, 0.11) ⊕⊕⊕⊝ moderatea −0.03 (−0.27,0.22) ⊕⊕⊕⊝ moderatea
Hemoglobin (change in
g/L)
3,851 (5 studies) 2.18 (1.02, 3.35) ⊕⊕⊕⊝ moderatea 1.98 (0.74,3.21) ⊕⊕⊝⊝ lowa,b
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Note: Findings based on the analysis of main effects of 19 studies providing individual participant data.
Abbreviations: CI, confidence interval; STH, soil transmitted helminth.
aDowngraded for study limitations—obtained only a selected sample of IPD from 19 out of 41 eligible studies.
bDowngraded for imprecision.
Summary of findings table 2: Deworming with praziquantel alone or in combination with any STH deworming compared to placebo for
children in STH endemic areas
Summary of findings table 3: Deworming with any STH drug with iron or micronutrients compared to placebo for children in STH endemic areas
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2 | BACKGROUND
2.1 | The problem, condition or issue
Soil transmitted (or intestinal) helminths and schistosomes affect
millions of children worldwide. There are four species of STH: A.
lumbricoides (roundworm), Necator americanus and Anyclostoma
duodenale (hookworms), and Trichuris trichiura (whipworm). The five
species of schistosomes which affect humans include: Schistosoma
mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma
intercalatum (which causes intestinal schistosomiasis) and Schistosoma
haematobium (which causes urinary schistosomiasis).
Mass deworming is applied widely to reduce the consequences of
helminth infection, and there have been numerous studies on the effects
of deworming on growth, cognition and learning outcomes in children
over the past several decades. Systematic reviews and meta‐analyses
based on aggregate results of the effect of mass deworming on health
and education outcomes are conflicting with some showing benefit
(Croke, Hicks, Hsu, Kremer, & Miguel, 2016; Hall, Hewitt, Tuffrey, & de,
2008) and others not (Taylor‐Robinson, Maayan, Soares‐Weiser, Done-
gan, & Garner, 2015; Welch et al., 2017). Debate has ensued about
whether these conflicting results are due to the influence of variations in
effect across individual‐level characteristics such as whether children are
infected or not and intensity of infection (Bundy, Kremer, Bleakley, Jukes,
& Miguel, 2009; Hotez et al., 2007; Montresor et al., 2015) as well as
setting characteristics such as the sanitation environment and rapidity of
reinfection (Campbell et al., 2016).
2.2 | The intervention
Mass deworming for STH infection and schistosomiasis is recom-
mended one to four times per year in order to reduce worm burden
in endemic areas in the updated World Health Organization
guidelines, depending on prevalence of worm infection (WHO,
2017). These updated WHO guidelines cite the Campbell and
Cochrane systematic reviews on deworming which both concluded
there was little to no effect of deworming on child health outcomes
which included growth, anaemia and cognitive outcomes (Taylor‐
Robinson et al., 2015; Welch et al., 2016). Mass deworming can be
applied to school‐aged children or whole communities. Selective
treatment of infected individuals is rarely done due to the high cost
of screening for infection.
The drugs used include albendazole, mebendazole, levamisole,
ivermectin and piperazine for STH infection and praziquantel for
schistosomiasis. These drugs are usually provided as pills, are
inexpensive and can be administered by schoolteachers or parents.
The drugs are considered to have few minor and transient side
effects, such as gastrointestinal discomfort, headache, nausea,
dizziness, oedema, myalgia and vomiting (WHO, 2017).
Mass deworming is sometimes accompanied by iron, micronu-
trient or food supplementation in order to correct nutritional
deficiencies that may have been caused by worm infections (de Gier,
Campos Ponce, van de Bor, Doak, & Polman, 2014; Friis et al., 2003;
Nga et al., 2009; Rajagopal, Hotez, & Bundy, 2014; Taylor, Jinabhai,
Kleinschmidt, & Jogessar, 2001). In addition, water and sanitation
measures may be implemented with mass deworming to reduce
exposure and transmission of infections.
2.3 | How the intervention might work
Even with heavy infections, the nutritional requirements of intestinal
worms relative to their human hosts are small. The harm to child
welfare is expected to be caused by three factors: (a) malabsorption,
(b) tissue damage and bleeding and (c) loss of appetite (Crawley,
2004). STH infections may cause malabsorption of nutrients in their
hosts because of damage to the gastrointestinal surfaces. Hookworm
infections are associated with anaemia, thought to be due to
hookworm feeding on host tissue and to bleeding when they move
from one site to another (Hall et al., 2008). Intestinal infections may
also lead to reduced appetite which may negatively influence both
growth and attention in school.
Deworming drugs are over 90% effective at reducing the worm
load in individuals and are expected to reduce the prevalence of
worm infection in the community as well as the intensity of infection
in individuals (Figure 1). Reducing the prevalence and intensity of
infection is expected to improve child nutritional status due to the
mechanisms described above of reducing blood loss, reducing
damage to gastrointestinal surfaces and improving appetite. Im-
proved nutritional status and appetite are expected to improve
attention in school and cognitive outcomes. Some have argued that
deworming alone is insufficient to improve child health outcomes
since the nutritional deficiencies caused by infections must be
corrected with food and/or micronutrients (Hall et al., 2008).
Many potential effect modifiers have been described in the
literature. Younger children may have a greater impact of
deworming since they are smaller in size and the impact of
infections may be greater on them (Hall et al., 2008). Girls may
benefit less from deworming if they have lower school atten-
dance (thus, not receiving deworming given at school) and if there
is preferential distribution of food or other resources at home
which could influence child welfare. Children who are stunted for
age at three years of age may not be able to benefit as much in
terms of growth. Conversely, children who are underweight may
benefit more from deworming than those of normal weight
(Hall et al., 2008). It is expected that benefits of deworming
would only accrue to those who are infected, and even more so to
those with heavier infection intensity (Hall et al., 2008). Low
socioeconomic status is expected to be correlated with other
features such as exposure to repeat intestinal infections,
including those that cause diarrhoea, and thus children with
lower socioeconomic status may not achieve as much benefit as
less poor children.
Reinfection is expected to depend on the prevalence and
intensity of infection as well as environmental factors such as the
water and sanitation environment and hygiene practices in the
community.
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2.4 | Why it is important to do the review
A recent Campbell systematic review and network meta‐analysis
(NMA) by members of our team (V. W., P. T., G. A. W., E. G., Z. B.),
with 47 randomised trials and >1 million children, found little to
no overall effect on growth, attention and school attendance
(Welch et al., 2016). With NMA, we were able to explore the size
of effect with different types and frequency of drugs and their
combination with food or micronutrients; none of which con-
tributed to larger effects. Our review also did not find larger
effects in subgroups of children at the aggregate level across
characteristics such as age, baseline nutritional status, preva-
lence or intensity of infection that have been postulated to be
important (Welch et al., 2016). These analyses were conducted at
the study level, rather than using data for each individual child,
which limits the power to detect effect modification by individual
participant characteristics. This review was therefore unable to
identify whether mass deworming was more effective for children
with certain characteristics. There was substantial unexplained
heterogeneity between studies, with some studies finding larger
effects than others, and no single individual‐level, setting‐level or
methodology characteristic explaining this variation. Thus, we
concluded that our analysis of effect modifiers was limited by the
aggregate level data.
Our previous review was conducted using NMA, which allowed
the comparison of treatments which had not been directly compared
in head‐to‐head trials. NMA also allowed for the assessment of the
role of multicomponent interventions (such as deworming combined
with other parasite control interventions, food or micronutrients).
Because there are several drugs used for mass deworming, this
allowed the assessment of heterogeneity related to the type of drug,
frequency and use of concomitant interventions.
IPD meta‐analysis has been called the “gold standard” in
meta‐analyses for exploring individual level characteristics and
their association with effects (Stewart, 1995). Advantages of IPD
meta‐analysis include improving data quality, enabling standar-
disation of outcomes, clarifying risk of bias and increasing the
power to assess the interaction of participant characteristics with
effect size (Dagne, Brown, Howe, Kellam, & Liu, 2016; Stewart
et al., 2015). Furthermore, IPD analysis can explore the size and
direction of differences in effect, thus assessing whether there is
F IGURE 1 Logic model for deworming effects
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a greater benefit for some participants (Early Breast Cancer
Trialists’ Collaborative Group, 1990). Another advantage of IPD
is that they usually require an international collaborative effort,
involving trial authors, who may help to identify more relevant
trials, and also contribute to an agreed analysis plan and shared
understanding of the results.
While failure to obtain some datasets may lead to selection bias if
there are systematic reasons why some studies do not provide full data,
methods have been developed to combine IPD with aggregate data
(when IPD is not available for some studies) in NMA (Donegan,
Williamson, D’Alessandro, & Smith, 2012; Sutton, Kendrick, & Coupland,
2008).
We decided in collaboration with several authors of primary
trials that there would be value in conducting an IPD meta‐
analysis to explore the question of whether mass deworming is
more effective for subgroups of children defined by character-
istics such as infection intensity or status, age or nutritional
status. This understanding could help to develop targeted
strategies to reach these children better with deworming and
guide policy regarding deworming.
3 | OBJECTIVES
The primary objective is to use IPD NMA to explore whether the
effects of different types and frequency of deworming drugs as
well as their combination with food or micronutrients on
anaemia, cognition and growth vary with child‐level and study‐
level characteristics (see Table 1), specifically: intensity of
infection (as assessed by egg count), infection status (including
species of worm), age, nutritional status, socioeconomic status
and sanitation environment.
4 | METHODOLOGY
The protocol was registered with the Campbell Collaboration (Welch
et al., 2018) and reported according to the preferred reporting items for
systematic reviews and meta‐analyses for protocols (PRISMA‐P; Moher
et al., 2015). Results of the review are reported using the PRISMA of
individual patient data (PRISMA‐IPD) Statement (Stewart et al., 2015)
and the PRISMA for network meta‐analyses (PRISMA‐NMA).
4.1 | Criteria for including and excluding studies
We included studies which met the following eligibility criteria:
4.1.1 | Types of study designs
We included randomised and quasirandomised trials. For the purpose
of determining whether specific individual‐level and environment‐
level characteristics are associated with greater effects of deworm-
ing, there is sufficient evidence from over 70 randomised trials with
over 100,000 children to include only randomised and quasirando-
mised trials. We included studies reported in abstract form at a
conference as well as unpublished studies. We sought full datasets
from all studies and carried out the same methods for data checking
and quality for all studies.
4.1.2 | Types of participants
Children aged 6 months up to 16 years. We excluded studies with
<100 participants because of the time and effort required for each
dataset and the information gained from smaller studies would be
small compared to larger datasets. We did not exclude studies on the
basis of attrition rate from the study.
4.1.3 | Types of interventions
Mass deworming using any drugs for STH or schistosomes with or
without cointerventions such as food, micronutrients, iron or hygiene
interventions. Eligible drugs include (but are not limited to)
albendazole, praziquantel, levamisole, ivermectin, diethyl carbama-
zine, pyrantel, piperazine, metrifonate, hycanthone and tetramisole.
We included studies with combined approaches to parasite
elimination such as albendazole and praziquantel. Also, because
deworming may be used in combination with iron, food or hygiene
promotion, we included studies with multiple component interventions.
Studies were included with placebo, control, or other active
interventions (e.g., vitamin A, iron, hygiene promotion) as comparators.
As NMA depends on the assumption of transitivity (that
participants could be randomised to any one of the treatments;
Salanti, 2012), we planned to conduct two evidence networks of
jointly randomizeable interventions of drugs given for two indica-
tions. First, we assessed the evidence network of interventions given
for STH which includes different frequencies of albendazole,
mebendazole, levamisole, pyrantel, piperazine, ivermectin and tetra-
misole with or without micronutrients or food. These are considered
jointly randomizable because they are given for the same indication,
and many have been compared in multiarm trials (Salanti, 2012).
TABLE 1 Potential effect modifiers at child‐level and environment
level
Child‐level Environmenta
Age Population level prevalence
Sex Population level intensity
Nutritional status Water and sanitation environment
Infection status
Socioeconomic status
Intensity of infection
(including type of worm and
duration of infection)
aEnvironment‐level factors were not entered into the same model as
individual‐level modifiers because these factors are likely multicollinear.
Instead, we planned to explore these factors with sensitivity analysis.
WELCH ET AL. | 7 of 51
Secondly, we considered the evidence network of interventions
given for schistosomiasis (praziquantel, metrifonate, hycanthone)
with or without micronutrients or food.
4.1.4 | Types of outcome measures
The primary health outcomes were change from baseline in: weight
(kg), height (cm), plasma ferritin, cognition and haemoglobin (g/L). We
included studies which measured weight, haemoglobin, plasma
ferritin, cognition or height. Cognition could be measured using
scales that measured development (e.g., Raven’s matrices) or tests
that assessed attention using digit recall.
We did not exclude on the basis of reported outcomes since
some measured outcomes may not be reported in trial reports or
abstracts.
We used the available data on age and sex to calculate height for
age, weight for age and weight for height for children <5 years using the
2006 child growth standards (using WHO software Anthro version
3.2.2) and body mass index (BMI) for age for children aged five or older
using the WHO Reference 2007 (using WHO AnthroPlus software).
Effects on infection intensity and status were assessed as secondary
outcomes. Adverse effects of deworming were assessed in prior
systematic reviews as minor and uncommon and the results are not
contested, thus we did not assess adverse effects in this review.
Since the primary objective of this systematic review is to assess
effect modification, particularly as it relates to infection status and
intensity, we excluded studies that did not measure baseline infection
prevalence of at least one of the STH or schistosomes.
4.1.5 | Duration of follow‐up
For weight and height, we included data from studies >4 months in
duration because we considered this as a minimum duration to
observe differences in growth based on clinical expertise of
nutritionists on the team and decided a priori. However, for
haemoglobin and ferritin status, changes may occur sooner, so study
duration was not be used as an exclusion criterion. While infection
status and infection intensity are affected much sooner than this,
these are not primary outcomes of interest since there is no question
that deworming drugs reduce infection load. We assessed infection
intensity and status at baseline as indicators of the force of infection
in the population. We collected data at each available time‐point and
aimed to explore study duration as a covariate in the model.
4.1.6 | Types of settings
The settings included any area where STH or schistosomes were
described as endemic.
4.2 | Search strategy
We adapted the search strategy used for a previous Campbell review
by members of our team (Welch et al., 2016) and updated the search
to March 27, 2018. See search strategy in Appendix. We searched in
the following databases: MEDLINE, CINAHL, LILACS, Embase, the
Cochrane Library, Econlit, Internet Documents in Economics Access
Service (IDEAS), Public Affairs Information Service (PAIS), Social
Services Abstracts, Global Health CABI and CAB Abstracts.
We searched the System for Information on Grey Literature in
Europe (SIGLE)‐ended in 2005. We searched websites of relevant
organisations such as the World Bank, World Food Program and
International Food Policy Research Institute, as per the prior
Campbell review (Welch et al., 2016).
We also contacted authors of studies and members of our
advisory board for any unpublished studies or grey literature
reporting eligible studies. We checked reference lists of relevant
studies and reviews.
Titles and abstracts were screened in duplicate by two reviewers.
We pilot‐tested the screening criteria at both title and abstract
screening stage and full text stage. We used the PRISMA flow
diagram to report eligibility of studies. We retrieved full text of all
studies which passed this first level screening. The full text review
was also done in duplicate by two reviewers, and agreement was
reached by consensus. Disagreements were resolved by consultation
with a third reviewer. No language limits were applied. The research
team had expertise in English, Portuguese, French and Spanish, and
translation would have been sought if studies were found in other
languages.
4.3 | Description of methods used in primary
research
Randomized controlled trials (RCTs) of deworming include two‐arm
trials as well as factorial trials, with children allocated either
individually or by cluster‐randomisation (e.g., by village or school).
4.4 | Details of study coding categories
Details of the populations, interventions, comparators, outcomes and
study design were extracted in duplicate by two reviewers, using a
pretested form, designed for a previous Campbell review on
deworming for children (Welch et al., 2016). This extraction includes
details about the context, setting and environment, as well as
sociodemographic details, and details about the frequency, delivery
method and dose of interventions.
Two independent reviewers appraised each study with the
Cochrane risk of bias tool which assesses selection bias, performance
bias, detection bias, attrition bias and reporting bias (Cochrane
Handbook; Higgins, Altman, & Sterne, 2011). Disagreements were
resolved by discussion or consultation with a third reviewer.
We appraised the GRADE certainty for each outcome for each
comparison by two independent reviewers, using the GRADE
approach for NMA (Puhan et al., 2014). GRADE certainty (quality)
“reflects our confidence that the estimates of the effect are correct.
In the context of recommendations, quality reflects our confidence
that the effect estimates are adequate to support a particular
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recommendation. “Quality as used in GRADE means more than risk
of bias and so may also be compromised by imprecision, incon-
sistency, indirectness of study results, and publication bias.” (Balshem
et al., 2011). The two reviewers discussed ratings and reached
consensus. Disagreements were resolved by consulting a third
reviewer.
We developed a summary of findings table for each main
comparison to show the effects for the outcomes of weight, height
and haemoglobin, along with the quality of evidence (using GRADE
certainty).
4.5 | Statistical procedures and conventions
Data were prepared into a Microsoft Excel spreadsheet with the
same fields for every study. Since we only included RCTs, we
considered the missing values for each variable as missing at random
(MAR) based on observed data (Joshi, Royuela, & Zamora, 2013).
We used multiple imputation to impute the missing values for
baseline and outcome variables based on the assumption of MAR
(Bell, Fiero, Horton, & Hsu, 2014; Groenwold, Moons, & Vanden-
broucke, 2014; Jakobsen, Gluud, Wetterslev, & Winkel, 2017) and
created five complete datasets using Proc MI in SAS9.4/STAT (SAS
Institute Inc., Cary, NC). All model estimates and standard errors
were obtained by fitting the model to each of these five imputed
datasets and aggregating results across them using Rubin’s Rule
which incorporates uncertainty due to imputation. Proc MIANALYZE
in SAS 9.4/STAT was used to obtain the aggregation of estimates
across imputed datasets.
Descriptive characteristics of each study are presented, with
details on the child characteristics, environment, worm species,
prevalence, and intensity of infection, geographic location, interven-
tions, comparator and outcomes and risk of bias assessment.
We accounted for clusters (such as villages, schools or house-
holds) as nested within each study.
We analysed IPD datasets to check for comparability with the
primary published papers. We calculated the standardised difference
between the published data and the IPD received from authors for
baseline characteristics and baseline outcome assessment. For
endline, we replicated the effect measures reported in study
publications and calculated the standardised difference between
the IPD received and the study report (Austin, 2009).
As with our previous Campbell review, we used a two‐step
process to meta‐analysis. We conducted pairwise analyses for each
comparison of interest by entering all IPD data into a multilevel
model, with each study as one cluster. We expected considerable
heterogeneity between studies for each outcome based on our
Campbell review; therefore, we used a random effects model. We
assessed mean differences in change from baseline for weight (kg),
height (cm) and haemoglobin (g/L). We intended to assess plasma
ferritin (mcg/L) but too few studies reported this outcome (seven
studies with 6,318 participants). The Advisory board, based on
clinical and methodological expertise, decided that there were
insufficient studies to conduct effect modification analyses and that
basic random effects meta‐analysis could be misleading.
For cognition, we analysed measures of motor and cognitive
development separately. We analysed measures of attention sepa-
rately from developmental outcomes. We did not combine different
measures of cognition.
We accounted for clustering as above by nesting clusters within
studies. We decided on a set of predefined covariates with advice
from our advisory board and coauthors. We accounted for the
covariates of sex, age, infection intensity for each type of agent,
socioeconomic status, maternal education and baseline nutritional
status in the model. We assessed heterogeneity using visual
inspection of forest plots for pairwise analyses as well as statistical
tests of heterogeneity (I2).
We conducted NMA with IPD, using a frequentist approach for
random‐effects NMA. The covariates were identified by the Study
Advisory Group, namely: age, sex, baseline nutritional status (weight
and height), haemoglobin and infection intensity. The effect estimate
chosen was the mean difference for the continuous outcome of
interest. The general linear mixed model (GLMM) follows a normal
distribution using a mixed linear regression model. Random effect
GLMM was conducted with two random effects considered in the
model: random effect “trial” accounts for the response variables of
patients within a given trial being correlated; and random effect
“Patient’s clusters” which accounts for the correlation of responses
between any two patients from the same clusters (such as villages,
schools or households) within a given trial. We expected to have a
connected network of trials to allow direct and indirect comparisons
based on our Campbell review and NMA (see Figure 12, full evidence
network for weight; Welch et al., 2016). We used the GLIMMIX
procedure in SAS 9.4/STAT (SAS Institute Inc.) for the GLMM NMA,
considering models that account for multiarm trials and adjust for the
covariates identified. Results are summarised as point estimates with
95% confidence intervals (CIs).
4.6 | Assessment of clinical and methodological
heterogeneity within treatment comparisons
Within GLM, the explanatory model included covariates at the study
level (e.g., methodological quality) and participant characteristics
(anaemia, nutritional status, infection intensity, age, sex). We
constructed forest plots for unadjusted direct treatment comparisons
and adjusted treatment comparisons and assessed heterogeneity by
visual inspection. Any study level or participant‐level covariates that
were statistically significant would have been analysed using
subgroup analyses. We compared participant characteristics and
trial methodology in tables.
4.7 | Assessment of transitivity across treatment
comparisons
Transitivity cannot be assessed statistically. With IPD, we have more
opportunity to account for and model heterogeneity. As proposed by
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Salanti (2012), we used IPD to assess the distribution of the child‐
level effect modifiers from Table 1 in each comparison to assess the
plausibility of the transitivity assumption (Salanti, 2012). As above,
transitivity is considered plausible since the treatments in each
model (STH and schistosomiasis, respectively) are provided for the
same indication and many of the treatments and their cointerven-
tions have been included in multiarm trials (as shown by the prior
review by our team: Welch et al., 2016).
4.8 | Assessment of statistical heterogeneity
For this IPD NMA, we assumed equal variances across comparisons
within network. This assumption was tested using the Levene test.
4.9 | Assessment of statistical inconsistency
Inconsistency in an NMA is defined as a disagreement between the
direct estimates (from direct comparisons of treatments) and indirect
estimates (which are derived from the network comparisons). With
GLMM we were unable to perform a test for model fit and
consistency therefore we assessed underlying assumptions about
consistency between indirect and direct evidence by comparing
direct effect estimates with NMA effect estimates (direct and
indirect evidence).
4.10 | Publication bias
A funnel plot would have been plotted for comparisons and outcomes
with >10 studies. We used Egger’s test for asymmetry and visual
inspection to assess the presence of publication bias and/or selective
reporting in the entire corpus of randomised trials of deworming
versus control for children (which includes some studies that were
not eligible due to missing baseline data on infection intensity and
some studies which were eligible but did not provide data).
We did not rank interventions because there is controversy as to
the utility of ranking.
4.11 | Subgroup analyses
Provided sufficient data was available to inform the evidence
network, subgroup analyses were conducted to assess effects across
both child‐level as well as environment‐level characteristics. We
compared the results of models with subgroup analyses by assessing
the size of quantitative or qualitative differences in effects, the
statistical significance of tests for interactions, assessing between‐
study variance and assessing the goodness of fit of the models using
the likelihood ratio.
The following child and environment level effect modifiers were
planned:
Child level:
• Individual‐level intensity of infection with ascaris, trichuris and
hookworm (across four levels of none, light, moderate and heavy,
using the WHO cutoffs for each helminth (http://apps.who.int/iris/
bitstream/10665/44671/1/9789241548267_eng.pdf)
• Stunting (HAZ> −2.0, HAZ < −2.0 to −3.0, HAZ < −3.0)
• Undernutrition (defined by WAZ cutoffs for children <5 years of age
(http://apps.who.int/iris/bitstream/10665/44129/1/9789241598163_
eng.pdf?ua=1) of WAZ>−2.0, WAZ< −2.0 to −3.0, WAZ<−3.0) and
by BMI for age (BAZ) cutoffs for children aged 5 years or older
available at http://www.who.int/growthref/who2007_bmi_for_age/en/)
using BAZ>−2.0, BAZ<−2.0 to −3.0, BAZ<−3.0),
• Anaemia (using WHO cutoffs by age and altitude of nonanaemic,
mild, moderate and severe, http://www.who.int/vmnis/indicators/
haemoglobin.pdf)
• Age (<5 and ≥5 years of age)
• Sex (male/female)
• Socioeconomic status: socioeconomic status is measured in
different ways in studies (e.g., questionnaires, asset indices,
quintiles). We planned to assess whether the measurement of
socioeconomic status could be compared across study settings and
time. We decided this was not possible therefore we did not do a
planned sensitivity analysis with children in the poorest tertile.
Before conducting subgroup analyses, we assessed the distribu-
tion of each variable. If there were insufficient children in some
categories, the levels were combined (see results).
We planned to assess socioeconomic status of household or
parents and maternal education as effect modifiers, but data was
insufficient (see results).
Environment level:
• Study level sanitation and hygiene environment, as reported by
studies was assessed to consider whether environments can be
classified according to consistent system
• Study‐level prevalence (using WHO cut‐offs for each worm‐type,
as above)
• Study‐level intensity of infection (using WHO cut‐offs for each
worm‐type, as above)
As noted in Table 1, environment level characteristics were not
entered into the model. They were assessed by sensitivity analyses.
We expected poor reporting on these details in the articles based on
our prior Campbell review, but some studies may have collected
information on this at the study level that were not reported in the
paper publications. We assessed whether there was sufficient data on
the geographic location and date of the studies to assess study‐level
prevalence generated by the Global Atlas of Helminth Infections.
4.12 | Sensitivity analyses
Provided sufficient data was available to inform the evidence
network, we conducted sensitivity analyses to assess robustness of
results when restricted to studies at low risk of bias for sequence
generation, allocation concealment and blinding of participants. We
assessed whether results were robust to excluding imputed data (i.e.,
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complete case analysis). We assessed sensitivity to restricting to
studies published in 2008 or later (last 10 years).
Data were housed at a secure data warehouse at the Bruyère
Research Institute, following the personal health information act.
Data were transferred to SAS as a common platform for all
studies, using a common data dictionary. V. W. checked IPD data
for consistency immediately upon receiving datasets. For exam-
ple, we checked for outlier individuals (e.g., with ages outside of
eligibility criteria, duplicate participant IDs, unrealistic
date ranges). We compared the IPD from authors with the
aggregate data reported in the articles. Any missing or unusual
data were flagged for discussion with the trial author or
statistician by V. W. We asked for clarification from the authors
to establish reasons for the errors, and corrected them if
possible. Any requests for authors were discussed when the data
was provided, such as clarification of trial risk of bias, conduct or
eligibility criteria. We ran the same statistical analysis as the
authors to check for consistency with the published paper
(Stewart et al., 2015).
We requested statements of ethics approval from each
study. No studies were identified that did not receive ethics
approval. We requested that all data be transferred without any
identifiers.
4.13 | Treatment of qualitative research
We did not include qualitative research.
5 | RESULTS
The results of this review are reported according to the PRISMA‐IPD
and PRISMA‐NMA reporting guidelines (checklists in Table S1).
5.1 | Search results
We searched all databases up to March 27, 2018. We also retrieved in
full text all 299 primary studies included in eight previous reviews
(Danso‐Appiah, Olliaro, Donegan, Sinclair, & Utzinger, 2013; Grimes et al.,
2014; Kramer, Zhang, Sinclair, & Olliaro, 2014; Salam, Haider, Humayun,
& Bhutta, 2015; Salam, Maredia, Das, Lassi, & Bhutta, 2014; Strunz et al.,
2014; Taylor‐Robinson et al., 2015; Welch et al., 2016).
We screened 14,034 records for inclusion. We screened 340
studies in full‐text. We assessed 41 studies of deworming for STH
and 14 studies of schistosomiasis treatment as eligible for inclusion.
One study included treatments for both STH and schistosomiasis
(Olds et al., 1999), and is included in both counts (Figure 2).
A total of 285 studies were excluded because they did not meet
eligibility criteria, due to lack of infection intensity data (n = 14), <3
months (n = 9) and wrong study design (n = 262; Table S3). We
identified one ongoing study of albendazole (Table S4).
5.2 | Contacting authors and yield of studies
We contacted first authors of all eligible studies by email outlining
the study purpose and inviting them to join the Deworming
Collaborative. If there was no reply, contact with all authors was
then made by email or using other contact information such as
Researchgate and twitter. Authors were contacted in their language
if possible (French, Portuguese).
For STH, we received complete data from 19 out of 41 published
studies (46%) (Tables S5), which represented 79% of all children
included in those eligible STH trials (Figure 3).
The retrieval of data was better for studies conducted after 2000,
with a yield of 15 out of 22 published studies (68%) and 90% of
participants randomised to eligible studies (Figure 4).
For studies conducted before 2000, we received only four out of
19 studies (21%), and 39% of participants randomised (Figure 5).
For schistosomiasis, we received data from only two out of
14 studies (14%) (Table S6), representing 37% of participants
randomised to eligible studies (Figure 6). We decided not to
pursue an analysis of schistosomiasis studies because of the risk of
misleading results with an inadequate representation of available
studies.
All study authors who provided data signed a data transfer
agreement (Appendix 2).
5.3 | Characteristics of studies
5.3.1 | Studies contributing data: Settings,
participants, size of studies
The 19 studies which provided data were conducted in Tanzania
(Beasley et al., 1999; Beasley, 1995; Stoltzfus et al., 1997, 2004), Sri
Lanka (Ebenezer et al., 2013), Kenya (Friis et al., 2003; Miguel &
Kremer, 2004; Olds et al., 1999), Vietnam (Hall, Hanh, Farley, Quynh
and Valdivia, 2006, Le Huong, Brouwer, Nguyen, Burema & Kok,
2007; Nga et al., 2009), China (Liu et al., 2017; Yap et al., 2014), Cote
d’Ivoire (Rohner et al., 2010), Bangladesh (Rousham and Mascie‐
Taylor, 1994), Indonesia (Wiria et al., 2013), Nigeria (Kirwan et al.,
2009), Uganda (Ndibazza et al., 2012) and the Philippines (Solon
et al., 2003) (Tables 2 and S7).
Three of these studies were screen and treat (SAT) studies: Yap
et al. (2014), Beasley et al. (1999) and Beasley (1995). We decided to
include these in the model since our model is designed to adjust for
infection intensity.
Seven studies were cluster RCTs, with the unit of randomisation
as the household (Stoltzfus et al., 2004; Wiria et al., 2013), the village
(Liu et al., 2017), and school (Ebenezer et al., 2013; Hall et al., 2006;
Miguel & Kremer, 2004; Stoltzfus et al., 1997). The study duration
ranged from 4 to 45 months. The median sample size was 486 (range,
124–15,881). Interventions included albendazole, mebendazole,
praziquantel at different frequencies, iron supplements, micronu-
trient tablets and food (noodles or biscuits only) or beverages
fortified with micronutrient and/or iron. The median frequency of
deworming was every 4 months (range, 2–8 months).
WELCH ET AL. | 11 of 51
F IGURE 2 PRISMA flow diagram. *Number of STH studies and schistosomiasis studies adds to 56 (not 55 as in the figure) since one study
(Olds et al., 1999) is counted as both STH deworming and schistosomiasis deworming because it is a factorial trial. STH, soil‐transmitted
helminthiasis
F IGURE 3 Yield of STH studies and participants. STH, soil‐transmitted helminthiasis
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The median age of children in the studies was 10.8 years of age at
enrolment (interquartile range, 8.8–13.0) according to IPD. For
nutritional status, 16% of the children included in these studies were
below −2 for BMI for age, 33% were stunted and 50% were anaemic
(Table 3). The prevalence of infection was 45% for A. lumbricoides (31%
light infections <4,999 eggs per gram of stool [epg], 13% moderate
infection intensity from 5,000 to 49,999 epg and 1% heavy infection
intensity with >49,999 epg), 52% for T. trichiura(38% light intensity
<1,000 epg, 14% moderate between 1,000 and 9,999 epg and 0% heavy
>10,000 epg) and 45% for hookworm (38% light intensity <2,000 epg,
5% moderate between 2,000 and 3,999 epg and 2% heavy >4,000 epg).
Additional child and setting charateristics for the 19 studies with
<50% missing data are in Table S2.
5.3.2 | Characteristics of STH deworming studies
which did not provide data
Characteristics of studies that did not provide data are shown in
Table S8. The main difference in these studies is their year of
publication since we were more successful at obtaining data from
more recent studies.
F IGURE 4 STH yield of studies and participants for studies post‐2000. STH, soil‐transmitted helminthiasis
F IGURE 5 STH studies pre‐2000. STH, soil‐transmitted helminthiasis
F IGURE 6 Schistosomiasis study yield
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5.3.3 | Compared to the 2016 aggregate data
Campbell review
Seventeen studies which were included in our prior Campbell review
(Welch et al., 2016) were excluded because they were not randomised or
quasirandomised trials (n=2), had no baseline infection intensity data
(n=15). These studies are summarised in Table S9.
5.3.4 | Aggregate effect estimates of studies not
providing IPD
We compared the effect estimates of the studies which were eligible
but did not provide data, those that provided data and those which
were not eligible (no infection intensity, too small or too short).
Results for STH deworming versus placebo for weight gain (kg) are
shown in Figure 7. As can be seen on visual inspection, two studies
had much larger effects on weight gain than any others (Stephenson,
Latham, Adams, Kinoti, & Pertet, 1993; Stephenson, Latham, Kurz,
Kinoti, & Brigham, 1989). The heterogeneity with both of these
studies included was 90% as assessed by I2, suggesting that statistical
combining of these studies is inappropriate. As in our previous
Campbell review, we removed outliers to assess contribution to I2.
Removing Stephenson (1989), which we earlier assessed as having
imbalance in baseline covariates which may have influenced results
(Welch et al., 2016), resulted in an I2 of 71%, which we considered
acceptable for statistical pooling, following the Cochrane Handbook
guidance (Higgins et al., 2011). The test for interaction of effect was
not statistically significant (p = .10).
Details for height and haemoglobin for STH versus placebo
are shown in Appendix 3, comparison 1. The interaction test
for subgroup effects was not statistically significant for any of
these outcomes. However, the studies which were not included
were older (with 8/16 published before 2000) compared to the
studies which provided IPD (3/13 post‐2000). Also, the size of
effect was larger for studies which did not provide IPD or
F IGURE 7 Weight gain (kg) for STH versus placebo for studies providing IPD and studies not included in the IPD analysis. IPD, individual
participant data; STH, soil‐transmitted helminthiasis
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were not eligible for weight gain with an effect of 0.07 kg (95%
CI: 0.01, 0.13).
5.4 | Feasibility of conducting IPD meta‐analysis
We judged that we had insufficient data to conduct analysis of the
studies of deworming for schistosomiasis since we received only two
studies out of 13 eligible for analysis, and this represented 36% of
participants randomised to eligible studies.
For deworming for STH, we received IPD from 19 studies out of
41 considered eligible (46%) and 31,945 out of 40,525 participants
randomised (79%). We considered this was sufficient data to pursue
IPD meta‐analysis.
5.5 | Quality of studies
Overall, there was low risk of selection and performance bias in 47%
(9 of 19) studies. 47% (9 studies) had unclear risk of bias due to lack
of detail on allocation method or method of blinding. Overall, there
was a high risk of attrition bias in 37% (seven studies) of the included
studies. Attrition bias was judged high risk due to loss to follow‐up of
>20% of participants in these studies. Detection bias could not be
assessed in 58% (11 studies) of the studies and selective reporting
could not be assessed in 79% (15 studies) due to insufficient
information. No major baseline imbalance was found in 74% (14
studies) of the studies, judged according to the description of
baseline characteristics (Figures 8 and 9).
The overall risk of bias was similar for studies for which we were
unable to obtain data except for selection bias which was low risk in
only 4.5% (1 of 22 studies) and unclear in 91% (22 studies) and
blinding of personnel which was low risk in 18% (four studies) and
unclear in 72% (16 studies) due to lack of description of the method
of allocation or blinding (Figures 10 and 11).
5.6 | Preparation, replication, imputation,
measurement and estimation
As described in the methods, we followed four steps to prepare,
replicate, impute and calculate anthropometric Z scores.
F IGURE 8 Risk of bias graph for 19
studies that provided data
F IGURE 9 Risk of bias summary for 19 studies that provided
data
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5.6.1 | Preparation: missingness analysis
Of the 19 studies that met this review’s inclusion criteria, 14 studies were
missing <50% of data for outcomes and covariates at baseline and
endline, and were included in the main analysis (Table 4). For the studies
included in the main analysis, there was an average of 4% missing data at
baseline (range, 0–42%), and an average of 9% missing data at endline
(range, 0–31%). Five studies (Hall et al., 2006; Kirwan et al., 2009; Miguel
& Kremer, 2004; Rousham & Mascie‐Taylor, 1994; Wiria et al., 2013)
were missing more than 50% of outcome or covariate data at baseline or
endline, and were included in the complete case analysis only. Wiria et al.
(2013), Hall et al. (2006), and Miguel and Kremer (2004) were missing
more than 50% of data for all STH counts at baseline. Hall et al. (2006)
and Rousham and Mascie‐Taylor (1994) did not collect haemoglobin at
baseline nor endline. Wiria et al. (2013) and Kirwan et al. (2009) were
missing more than 50% of data on all outcome variables at endline.
Miguel and Kremer (2004) was missing height measures for all study
participants at baseline, and haemoglobin measures for all participants at
endline.
5.6.2 | Replication
Replication of the published study results was conducted for all 19
eligible studies. The standardised differences between the published
and replication results were at or below 0.10 for all outcome measures
and covariates at baseline and endline, with the exception of two
measures from the Ebenezer et al. (2013) study (baseline haemoglobin
and baseline age) (Table 5). The average standardised difference
between published study results and replication results at baseline and
endline were 0.014 (range, −0.13–0.15) and 0.015 (range, −0.09–0.07),
respectively. For every study, there was at least one instance where
the standardised difference could not be calculated at baseline or
endline because the published results did not report the covariate or
outcome measure in question (indicated as “NA” in Table 6).
5.6.3 | Imputation
We used multiple imputation for missing data at baseline and endline
and created five completed datasets.
F IGURE 10 Risk of bias graph for 22
studies that did not provide data
F IGURE 11 Risk of bias for studies not providing data
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5.6.4 | Measurement and estimation
Two studies (Ebenezer et al., 2013 and Yap et al., 2014) required
adjustments to haemoglobin measures due to high altitude. The
altitude correction method applied was:
= − × ( − )‐ ( × )eHb Hb 3.44 1 ,sea level measured 0. 000 633 Alt
where Hbsea level stands for the concentration after adjustment, and
Alt for altitude (m) (Dirren, Logman, Barclay, & Freire, 1994). The
mean altitude for each village was applied to each child in the village.
BMI for age, weight for age and height for age were calculated as
described above, using Anthro Software.
Distribution curves for effect modifier variables were prepared to
confirm there were sufficient numbers of children in each pre-
specified level to conduct subgroup analyses (Supporting Information
Figures). For individual‐level intensity of infection (any helminth,
Ascaris, hookworm, Trichuris), the distribution curves showed that
there were insufficient numbers of children with a high intensity level
of any helminth infection to justify the use of the WHO cutoffs for
each helminth, as originally planned. Consequently, tertiles for the
distributions were calculated and used to define the levels of the
subgroup analyses to assess the gradient of effect for each helminth
and for infection intensity (any helminth). The cutoffs used for BMI‐
for‐age z score, weight‐for‐age z score, and height‐for‐age z scores
were adjusted to include only two levels (≤−2SD, >−2SD) to
accommodate the lack of children with extreme scores at either
end of the distribution. Anaemia status was adjusted to two levels
(not anaemic, anaemic)1 for the same reason.
5.7 | Effect of deworming on infection intensity
The effect of deworming on infection intensity was assessed for each
study and each type of STH infection and found to be variable across
studies (see Appendix 4, Forest plots, comparisons 9 and 10). When
sorted according to year of publication, there was no visual trend of
greater infection prevalence between the years of publication of
these studies from 1999 to 2015. The complete case analysis (only
including children with complete data on infection prevalence) were
comparable to results conducted using multiple imputation for
baseline prevalence.
Six studies had relative risk reduction of A. lumbricoides infection
prevalence 20% or more when compared to the placebo group in A.
lumbricoides prevalence at endline (Beasley et al., 1999; Friis et al.,
2003; Le Huong et al., 2007; Nga et al., 2009; Stoltzfus et al., 1997,
2004) and these were included in a sensitivity analysis to assess
TABLE 5 Standardised differences between published and reproduced results for baseline outcome measures and covariates by eligible study
Studies Hb Weight Height Age Sex
Ascaris
lumbricoides
epg Hookworm epg
Trichuris
trichiura
epg
Beasley et al.
(1999)
0.00 NA NA NA NA 0.00 0.00 0.00
Beasley Tanbase NA NA NA NA NA NA NA NA
Ebenezer (2013)a 0.00, 0.15 NA NA −0.13, 0.00 NA NA NA NA
Friis (2003) −0.06, 0.007 −0.02, 0.025 −0.05, 0.04 0.00, 0.004 NA NA NA NA
Huong (2007) −0.08, 0.02 −0.10, 0.04 −0.01, 0.00 −0.02, 0.04 NA NA NA NA
Liu et al. (2017) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Ndibazza et al.
(2012)
NA NA NA 0.00 0.00 NA NA NA
Nga (2009) 0.00, 0.01 −0.01, 0.00 −0.01, 0.01 0.00 NA NA NA NA
Olds (1999) NA NA NA NA NA NA NA NA
Rohner (2010) −0.02, 0.01 NA NA −0.06, 0.00 NA NA NA NA
Solon (2003) −0.01, 0.00 0.00 0.00 −0.02, 0.02 NA NA NA NA
Stoltzfus (1997) NA 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Stoltzfus (2004) −0.08, 0.00 NA NA −0.09, 0.03 NA NA NA NA
Yap (2014) −0.01, 0.02 0.00 −0.01, 0.00 −0.02, 0.03 NA 0.00 0.00 0.00
Kirwan (2009) NA NA NA 0.00 0.00 0.00 0.00 0.00
Hall (2006) NA 0.00 0.00 0.00 NA 0.00 0.00 0.00
Miguel (2004) NA NA NA NA NA 0.00 0.00 0.00
Rousham (1994) NA 0.00 0.00 NA NA NA NA NA
Wiria (2013) NA 0.00 0.00 NA NA NA NA NA
Abbreviation: epg, eggs per gram of stool.
aStandardised differences between published and reproduced results > 0.10.
1Anaemia cutoffs were sex‐ and age‐specific as per the WHO’s Haemoglobin concentrations
for the diagnosis of anaemia and assessment of severity (World Health Organization, 2013).
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whether greater impact on A. lumbricoides prevalence was associated
with greater effects on growth or haemoglobin.
One study did not assess endline infection intensity (Liu et al., 2017).
5.8 | NMA‐IPD model development
We planned our analysis model a priori based on consultation
with the advisory group and our research team to consider study
design elements, outcomes, covariates and effect modifiers.
5.8.1 | Changes to analysis model
The effect on plasma ferritin levels was not assessed because only
seven studies measured this outcome (Beasley et al., 1999; Beasley,
1995; Le Huong et al., 2007; Nga et al., 2009; Rohner et al., 2010;
Stoltzfus et al., 1997, 2004) (Table 7).
Six out of 14 studies (Ebenezer et al., 2013; Liu et al., 2017; Nga
et al., 2009; Rohner et al., 2010; Solon et al., 2003; Stoltzfus et al.,
1997) measured effects on cognition outcomes. However, the
specific measures and methods used to assess cognition varied by
study. At the December 2017 meeting of the review investigators
and advisors (London, UK), it was decided to assess cognition (using
measures for attention and development) on a study‐by‐study basis.
Where measures were described with the same name (e.g., working
memory in Liu et al., 2017; Ndibazza et al., 2012; Nga et al., 2009),
the Advisory Group recommended not combining results across
studies since the translation and different contexts of the studies
could influence the tool’s application. Cognitive measures were
categorised as related to: (a) short‐term attention (e.g., digit recall),
(b) scholastic performance (e.g., math, language tests) or (c)
developmental outcomes (e.g. motor development, Raven’s index).
An insufficient number of eligible studies included measures for
maternal education and socioeconomic status, and the specific measures
used varied by study (Table 8). Five studies (Ebenezer et al., 2013; Liu
et al., 2017; Ndibazza et al., 2012; Nga et al., 2009; Yap et al., 2014)
included a measure for maternal education, and seven studies
(Beasley et al., 1999; Beasley, 1995; Liu et al., 2017; Ebenezer et al.,
2013; Ndibazza et al., 2012; Nga et al., 2009; Yap et al., 2014) included a
measure for socioeconomic status. Given the limited number of studies
and the variability in measures, these measures were not included as
covariates in the model.
The weight‐for‐height z score for children under 5 years
that was originally planned as a covariate was replaced by BMI‐for‐age
on the recommendation of the Advisory Group to avoid collinearity
between weight‐for‐age and height‐for‐age z scores.
Indicators for water and sanitation were not included as effect
modifiers because not all studies described water and sanitation
conditions (see Table 2—Characteristics of Included Studies). The
studies that did provide descriptions did not do so in a quantifiable
way that would allow comparison.
5.8.2 | Evidence network and feasibility assessment
for NMA
The full evidence network included 18 nodes (Figure 12) due to
different types of deworming (e.g., albendazole, mebendazole and
praziquantel), cointerventions (e.g., micronutrients) and frequency of
deworming. We considered the control arm of two studies as
equivalent to placebo (Liu and Miguel).
5.9 | Evidence network refinement
We ran the NMA‐IPD for the full network with 18 nodes, as above.
We excluded five studies with >50% missing data since we could not
impute missing data and adjusted analyses would be biased due to
the amount of missing data. We decided to include these five studies
in a “complete case” sensitivity analysis.
The results with the full evidence network were presented at a
meeting of the Advisory Group in June 2017 (Table S13: full network
—14 studies, 18 nodes). The Advisory Board decided that the full
network was too complicated to allow meaningful interpretation for
policy decisions.
The effects on weight gain, height gain and haemoglobin were not
statistically significant for the two types of STH deworming drugs:
albendazole and mebendazole. Since the WHO guidelines on
deworming (WHO, 2017) do not distinguish between the choice of
mebendazole or albendazole on the grounds of nutritional effects,
the Advisory board decided to collapse across type of STH drug.
With respect to praziquantel, results showed larger effects
on haemoglobin for all treatment comparisons which included
TABLE 6 Standardised differences between published and repro-
duced results for endline outcome measures by eligible study
Studies Hb Weight Height
Beasley et al. (1999) −0.09, 0 NA NA
Beasley (1995) NA NA NA
Ebenezer (2013) 0.00 NA NA
Friis (2003) −0.006,
0.069
NA NA
Huong (2007) 0.00 NA NA
Liu et al. (2017) 0.00 0.00 0.00
Ndibazza et al. (2012) −0.02, 0.00 0.00 −0.02
Nga (2009) 0.00 NA NA
Olds (1999) NA NA NA
Rohner (2010) −0.002, 0.01 NA NA
Solon (2003) −0.049,
0.008
−0.058,
−0.047
−0.06, −0.03
Stoltzfus (1997) 0.00 0.00 0.00
Stoltzfus (2004) 0.00 NA NA
Yap (2014) 0.00, 0.002 −0.003, 0.007 −0.007,
−0.005
Kirwan (2009) NA NA NA
Hall (2006) NA NA NA
Miguel (2004) NA NA NA
Rousham (1994) NA NA NA
Wiria (2013) NA 0.00 0.00
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praziquantel (e.g., Albendazole + praziquantel effect on haemoglobin
was 2.03 g/L, 95% CI: 0.56, 3.50) compared to effect of albendazole
alone on haemoglobin of 0.16 g/L, 95% CI: −0.86, 1.17). Praziquantel
is given in areas where schistosomiasis is endemic, and schistoso-
miasis is known to have effects of chronic inflammation in the
intestines, liver or urogeneital system which are linked to anaemia
and malnutrition (Colley, Bustinduy, Secor, & King, 2014). Thus, the
Advisory board decided to collapse all treatments which included any
type of praziquantel into one treatment node.
With respect to micronutrients, in the analysis of 18 nodes, we
found overlapping 95% CIs for iron fortified food or beverages
(−0.04 kg, 95% CI: −0.35, 0.27), iron tablets (−0.32 kg, 95% CI: −0.69,
0.06), micronutrient tablets (0.03 kg, 95% CI: −0.26, 0.32) or
micronutrient fortified food/beverage (0.04 kg, 95% CI: −0.17, 0.24)
on weight gain. Also, there were no differences in haemoglobin
effects (Table S13). Thus, the Advisory board decided to collapse all
iron and micronutrients into a single node.
Based on evidence of efficacy of micronutrients and iron on
childhood anaemia and iron deficiency (De‐Regil, Jefferds, Sylvetsky,
& Dowswell, 2011), the Advisory Board agreed that all micronu-
trients and iron could be collapsed together into one node. Similarly
STH deworming combined with any micronutrient or iron was
collapsed into a treatment node.
This revised, collapsed network was run, with separate nodes for
frequency of STH deworming to further explore the importance of
frequency in a network with eight nodes. The Advisory Group
recommended combining all helminth deworming drugs into one
node for high frequency dosage, and a second node for regular
frequency dosage. The rationale for keeping frequency separate was
that more frequent deworming could provide more constant levels of
lower worm burden.
At the November 2017 meeting of investigators and the Advisory
Group, the results for high versus regular frequency of STH deworming
were presented and considered not different (e.g weight gain for STH
deworming at high frequency was −0.01 kg, 95% CI: −0.13, 0.10) and for
regular frequency weight gain was 0.13 kg (95% CI: 0.04, 0.22)) hence
the network was further reduced to six nodes (Figure 13).
Since the results may be influenced by these decisions about
collapsing across nodes, the Advisory Board and research team
decided to also analyse the full network as a sensitivity analysis.
5.9.1 | Assessing feasibility of NMA with IPD
Assumptions of transitivity and consistency
Transitivity was considered plausible because we assessed the
distribution of child‐level effect modifiers across studies, and found
TABLE 7 Comparison of original analysis plan and actual model employed
Planned Actual
Design Study
Clusters
Treatment arms
Number of 6‐month periods
Study
Clusters
Treatment arms
Outcomes Change in weight (kg)
Change in height (cm)
Change in haemoglobin (g/L)
Change in cognition
Change in plasma ferritin
Change in weight (kg)
Change in height (cm)
Change in haemoglobin (g/L)
Change in cognition (by study only)
Covariates Age
Sex
Ascaris lumbricoides epg count
Hookworm epg count
Trichuris trichiura epg count
Haemoglobin
Height‐for‐age
BMI‐for‐age (5 years and older)
Weight‐for‐height (under 5 years)
Socioeconomic status
Maternal education
Age
Sex
A. lumbricoides epg count
Hookworm epg count
T. trichiura epg count
Haemoglobin
Height‐for‐age
BMI‐for‐age (all ages)
Effect modifiers Weight‐for‐age z score (<−3SD, −3SD, −2SD, >−2SD)
Height‐for‐age z score (<−3SD, −3SD, −2SD, >−2SD)
A. lumbricoides intensity (0, light, moderate, heavy)
Hookworm intensity (0, light, moderate, heavy)
T. trichiura intensity (0, light, moderate, heavy)
Any helminth infection intensity (0, light, moderate, heavy)
Anaemia status (none, mild, moderate, severe)
Age (1–5, >5 years)
Sex (female, male)
BMI‐for‐age z score (≤−2SD, >−2SD)
Height‐for‐age z score (≤−2SD, >−2SD)
A. lumbricoides intensity (tertiles)
Hookworm intensity (tertiles)
T. trichiura intensity (tertiles)
Any helminth infection intensity (tertiles)
Anaemia status (not anaemic, anaemic)
Age (1–5, >5 years)
Sex (female, male)
Abbreviation: BMI, body mass index; epg, eggs per gram of stool.
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TABLE 8 Maternal education, socioeconomic status, and cognition measures by eligible study
Studies Maternal education Socioeconomic status Cognition
Beasley (1999) NA House made of concrete (yes, no)
Owns home (yes, no)
Owns a sewing machine (yes, no)
Owns a radio (yes, no)
NA
Beasley (1995) NA House made of concrete (yes, no)
Flushing toilet (yes, no)
Owns home (yes, no)
Owns a sewing machine (yes, no)
Owns a bike (yes, no)
Owns a radio (yes, no)
NA
Liu et al. (2017) Mother has attended secondary
school (yes, no)
Individual level
Boarding at school
Ethnicity
Household level
Number of siblings
Number of pieces of durable assets
Parents who are working migrants (yes, no)
Mother has attended secondary school (yes, no)
Father has attended secondary school (yes, no)
Dirt floor (yes, no)
Dirt‐based latrines (yes, no)
Working memory index (digit span,
letter numbering sequencing)
Processing speed index (coding, symbol
search)
Ebenezer (2013) Total number of years in school Poor (yes, no)
Father’s total number of years in school
Math scores
Tamil scores
Single digit attention scores
Double digit attention scores
Ndibazza et al.
(2012)
Level of education (none,
primary, secondary, tertiary)
Household SES scored (1–6) based on building
materials of the home, number of rooms, and
items owned
General cognitive abilities (block design,
picture vocabulary scale)
Cognitive flexibility (Wisconsin card sort
test)
Measure of attention (picture search)
Working memory (sentence repetition,
verbal fluency, counting span, running
memory)
Motor abilities (coin box, balancing on one
leg)
Measure of planning (Tower of London)
Measures of inhibition (tap once tap
twice; shapes task)
Nga (2009) Level of education (illiterate,
primary, secondary, high
school, college)
Percentage of households classified as “poor” Raven’s coloured progressive matrices
test
Working memory (digit span forward, digit
span backward)
Processing speed index (coding, block
design)
Math scores
Vietnamese language scores
Rohner NA NA Raven score
Coding total
Symbols total
Target marking errors
Target marking time
Solon (2003) NA NA Verbal ability
Quantitative ability
Nonverbal ability
Total cognition
(Continues)
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similar distributions across studies for all covariates (Figures 2–13).
In addition, we found that the distribution of effect modifiers was
balanced across comparisons (Table S17). As shown by the evidence
network, the treatments are given for the same indication and
compared in the same studies, with numerous connected nodes in the
full network (with 18 nodes) as well as the collapsed evidence
network (six nodes; Table 9).
Methodological and clinical heterogeneity was considered appro-
priate for pooling by considering the settings, population character-
istics and interventions. Statistical heterogeneity within each treat-
ment comparison was tested by constructing forest plots for each
direct comparison. Heterogeneity as measured by the I2 statistic was
<75% for all direct comparisons (Appendix 3, Forest plots).
5.10 | Funnel plot
As above, the only comparison with >10 studies providing IPD was
STH deworming versus placebo, with nine studies with sufficient data
for multiple imputation of missing data, and four studies with >50%
missing data (Kirwan et al., 2009; Miguel & Kremer, 2004; Rousham
& Mascie‐Taylor, 1994; Wiria et al., 2013).
As planned, we constructed a funnel plot to assess the presence of
publication bias. To do this, we included all studies of STH versus
placebo from our previous Campbell review of deworming (Welch et al.,
2016) to compare the received data with the data which was either not
received or ineligible (due to lack of baseline infection intensity data).
The funnel plot of STH deworming versus placebo for the studies
for which we received data (circles) shows that the studies we
received include both positive and negative studies (Figure 14). The
studies which were not received had larger effects on weight gain
and were smaller (diamonds).
The Egger test for publication bias on the aggregate data of the
entire sample (n = 30 studies) was not statistically significant
(p = .249) for small study effects.
5.11 | Main effects
This section provides the overall results on our four primary outcomes:
weight, height, haemoglobin and cognition, using the collapsed evidence
TABLE 8 (Continued)
Studies Maternal education Socioeconomic status Cognition
Stoltzfus (2004) NA NA Language development (18 items)
Motor development (20 items)
Yap (2014) Parents’ level of education
(literate, primary, secondary,
above)
Parents’ level of education (literate, primary,
secondary, above)
Household income source (agriculture, teacher/
government official, own business, worker)
NA
Abbreviation: SES, socioeconomic status.
F IGURE 12 Full evidence network
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network, which we decided was the most clinically sensible and policy‐
relevant. The results are based on studies with a median duration of 7
months (ranging from 4 to 45 months).
These findings are summarised in three summary of findings tables.
Following this section, we describe effect modifier analyses for
each planned effect modifier for each outcome of interest.
A road map of all analyses is described in Table S10. Results for
main effects of NMA with IPD for the base case are in Table S11.
5.11.1 | Weight
Base case IPD‐NMA analysis
There were no statistically significant effects on weight gain (kg) for
any of the deworming combinations compared to placebo. For STH
deworming versus placebo, the effect on weight gain was 0.01 kg
(95% CI: −0.08, 0.11; Figure 15).
The head‐to‐head comparisons of deworming treatment combi-
nations produced results that were consistent in direction and size
with the results of the treatment versus placebo comparisons.
Direct evidence‐aggregate and IPD
For each comparison, we compared the IPD‐NMA result with the
results for the direct evidence from study results pooled at the
aggregate level (adjusted for covariates) and the direct evidence
pooled using IPD (adjusted for covariates).
In all cases, the effect estimates from direct evidence were of
similar size and direction as the IPD‐NMA indirect + direct effect
estimates (Table 10), and the heterogeneity of direct comparisons
was below an I2 of 75% (Table 11). The forest plot for one
comparison (deworming for STH vs. placebo) is shown in Figure 16.
The effect estimates for all other comparisons are shown in
Appendix 3 with details for each study for each comparison
(Appendix 3).
Sensitivity analyses
There were no qualitative (different directions of effects) nor
quantitative (different sizes of effects) differences in the analyses
conducted with no covariates (unadjusted analyses; Table S12). For
example, the unadjusted effect on weight gain was 0.01 (−0.08, 0.11)
for STH versus placebo.
The results of a complete case analysis with the same 14 studies
from the base case, where missing data were not imputed, was
congruent with the main effects described above (Table S12). For
example, the effect on weight gain for STH deworming versus
placebo was 0.03 kg (95% CI: −0.07, 0.13).
The complete case analysis with an additional five studies
(Hall et al., 2006; Kirwan et al., 2009; Miguel & Kremer, 2004;
Rousham & Mascie‐Taylor, 1994; Wiria et al., 2013) which had too
much missing data (>50%) for multiple imputation was congruent
with our base case analysis. For example, the effect on weight for
STH deworming versus placebo was 0.01 kg (95% CI: −0.11, 0.12).
Analysis of the NMA model restricted to studies at low risk of
bias yielded similar results (Table S12) for weight gain (kg) for STH
versus placebo (0.01 kg, 95% CI: −0.10, 0.12). However, there were
F IGURE 13 Final collapsed evidence network. *Five studies with >50% missing data are not shown in this figure. Four of these included STH
deworming versus placebo (Wiria, Kirwan, Miguel, Rousham) and one assessed STH deworming +micronutrients versus micronutrients (Hall
et al., 2006). STH, soil‐transmitted helminthiasis
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TABLE 9 Comparison of node constitution in full network, June 2017 collapsed network and November 2017 network model
Full network
Collapsed network1 (8 nodes)Jun 2017 Advisory Group
meeting
Collapsed network2 (6 nodes)November
2017 Advisory Group meeting
1 Placebo or control Placebo or control Placebo or control
2 Albendazole STH deworming with any drug at regular frequency STH deworming with any drug
3 Praziquantel STH deworming with any drug at high frequency Any STH deworming combination with
praziquantel
4 Albendazole with praziquantel Any STH deworming combination at regular frequency
with praziquantel with or without iron or
micronutrients
Any STH deworming combination with
praziquantel with iron or micronutrients
5 Albendazole (high) with
praziquantel with iron
Any STH deworming combination at high frequency with
praziquantel with or without iron or micronutrients
Any STH deworming with micronutrients or
iron
6 Albendazole (high) with
praziquantel
Any STH deworming at regular frequency with
micronutrients or iron
Micronutrients or iron alone
7 Iron fortified (food/beverage) Any STH deworming at high frequency with
micronutrients or iron
8 Iron supplement (tablet/liquid) Micronutrients or iron alone
9 Mebendazole (high)
10 Micronutrient tablet
11 Albendazole with praziquantel with
micronutrient tablet
12 Albendazole with micronutrient
fortified (food/beverage)
13 Mebendazole (high) with iron
fortified (food/beverage)
14 Mebendazole with iron tablet
15 Micronutrient fortified (food/
beverage)
16 Mebendazole (regular)
17 Mebendazole (high) with iron
supplement (tablet/liquid)
18 Albendazole (regular) with
praziquantel with iron
Abbreviation: STH, soil‐transmitted helminthiasis.
F IGURE 14 Funnel plot for weight gain
(kg) for all studies of STH deworming
versus placebo. STH, soil‐transmitted
helminthiasis
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larger effects for praziquantel with or without STH deworming
versus placebo (0.17 kg, 95% CI: −0.28, 0.62) compared to 0.04 kg
(−0.11 to 0.19) in base case) or praziquantel with STH deworming
and micronutrients or iron (0.34 kg, 95% CI: −0.10, 0.78) compared to
−0.03 kg, 95% CI: −0.27, 0.21). These latter comparisons also had
wider CIs due to smaller numbers of participants.
We assessed the full evidence network with 18 nodes with our 14
base case studies, with multiple imputation for missing data and adjusted
for covariates as a sensitivity analysis to allow comparison of separate
drugs such as albendazole and mebendazole at different frequencies to
our main model findings with the collapsed network. These analyses had
wider CIs (Table S12). In this analysis, we found some larger effects on
weight gain than in the collapsed model. For example, the effect of
mebendazole twice per year versus placebo was 0.25 kg (95% CI: −0.37,
0.86). For praziquantel alone versus placebo, the effect was 0.18 kg
(95% CI: −0.19, 0.56) compared to 0.04 kg (−0.11, 0.19) in the base case.
None of these effects were statistically significant.
One study had very precise results and received a lot of weight in
the meta‐analyses for weight and height gain (Nga et al., 2009). We
conducted a sensitivity analysis without this study and found the
same effect on weight gain for STH versus placebo (0.01 kg, 95% CI:
−0.08, 0.11). Other effect sizes were also of a similar magnitude and
direction as the base case.
As described above, there was variation in effect of deworm-
ing on infection prevalence at endline. We conducted a senstivity
analysis restricted to studies which were more effective at
reducing infection prevalence, defined as a a relative risk of 0.80
or lower when compared to the placebo group in A. lumbricoides
prevalence at endline (Beasley et al., 1999; Friis et al., 2003; Le
Huong et al., 2007; Nga et al., 2009; Stoltzfus et al., 1997, 2004).
The results of this sensitivity analysis show that for STH
deworming versus placebo, the effect on weight gain was
0.08 kg, 95% CI (−0.10, 0.26), whereas our basecase analysis
findings were 0.10 kg (95% CI: −0.08, 0.11).
Comparison of effect sizes for weight gain (kg) between received data
and studies that were not included in the analysis
We assessed whether the effects on weight gain were similar for
these studies which did not provide data (either because they did not
provide it or because they did not meet eligibility criteria) to the
studies which did provide data (Appendix 3). For the STH versus
placebo comparison, using aggregate data, the effect size for the
studies for which we received data was 0.02 kg (95% CI: −0.04, 0.08)
(13 studies, I2 12%) compared to an effect size for the studies we did
not receive of 0.13 kg (95% CI: 0.01, 0.25) (n = 15 studies, I2 71%).
F IGURE 15 Weight gain (kg), base
case, collapsed network, adjusted for
covariates
TABLE 10 Comparison of direct and indirect evidence for weight
gain (kg) for STH versus placebo
Analysis
Effect estimate of STH vs.
placebo, weight gain (kg)
Aggregate‐direct adjusted 0.05 (−0.02, 0.11), I2 = 11%
IPD‐direct adjusted 0.013 (−0.088, 0.115)
IPD‐NMA‐Direct + indirect
evidence (adjusted)
0.01 (−0.08,0.11)
Abbreviation: IPD, individual participant data; STH, soil‐transmitted
helminthiasis.
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The interaction test for subgroup differences was not statistically
significant (p = .10). The pooled effect of all 28 studies was 0.07 kg,
95% CI (0.00, 0.13).
The above analysis only includes studies which randomised STH
alone compared to a placebo or control arm. Studies with vitamin A, iron
or praziquantel as cointerventions are not included in this analysis since
we decided that STH deworming and cointerventions should be
considered as separate nodes. The latter analysis omits one study
(Stephenson et al., 1989) which was also omitted from our previous meta‐
analysis (Welch et al. 2016). In our previous systematic review, we
identified baseline imbalance in the Stephenson 1989 study for
hookworm prevalence (95% vs. 79%) and infection intensity (1,183 epg
vs. 394 epg for the control group). This baseline imbalance is larger than
expected by chance and may have biased the study to find larger effects
since sicker children were in the intervention group. The effect was 1.3 kg
greater weight gain with a single dose of albendazole (400mg) compared
to placebo after 6 months. When included in our analysis, the I2 was 89%,
suggesting pooling is inappropriate. There may have been other factors
related to this study which led to a larger weight gain than seen in any of
the other 28 studies of STH deworming versus placebo. The Stephenson
et al. (1993) study conducted in the same area in Kenya found an effect
of 1.1 kg on weight gain of a single dose of Albendazole over 8.2 months.
5.11.2 | Height
Height‐base case analysis
The effect on height gain for STH deworming versus placebo was
0.09 cm (95% CI: −0.08, 0.27). The effects for the other comparisons
were of similar magnitude (Figure 17).
The head‐to‐head comparisons of STH deworming treatment
combinations produced results that were consistent in expected
direction and size with the results of the treatment versus placebo
comparisons.
Direct evidence‐aggregate and IPD
Comparison of the analyses of height gain for STH versus placebo for
aggregate data, IPD direct estimates and IPD‐NMA estimates are
congruent in size and direction of effect (Table 12).
The forest plots for each direct evidence comparison were of
acceptable heterogeneity to carry out NMA (Table 13).
Sensitivity analyses
There were no qualitative (different directions of effects) nor
quantitative (different sizes of effects) differences in any of the
sensitivity analyses including: (a) unadjusted analyses, (b) complete
case (unadjusted), (c) studies at low risk of bias, (d) full model with 18
nodes and (e) complete case with additional five studies that had too
much missing data to be included in the adjusted models (Tables S12
and S13).
As an example, the effect sizes for the STH versus placebo
comparison for height gain are in the table below (Table 14).
Comparison of effect sizes for height gain (cm) between received data
and studies that did not provide data
We assessed whether the effects on height gain were similar for
these studies which did not provide data (either because they did not
provide it or because they did not meet eligibility criteria) to the
studies which did provide data (Appendix 3). The test for interaction
TABLE 11 Heterogeneity of direct evidence comparisons
Comparisons Effect estimate and heterogeneity of direct evidence (pooled at aggregate level)
STH deworming vs. placebo 0.05 (−0.02, 0.11), I2 = 11%, 9 studies
PZQ alone or with STH vs. placebo 0.04 (−0.12, 0.20) I2 = 0%, 5 studies
PZQ with MCN/iron vs. placebo 0.13 (−0.28, 0.54), I2 = 67%, 3 studies
STH deworming with MCN/iron vs. placebo 0.00 (−0.07, 0.08), I2 = 0%, 5 studies
MCN/iron vs. placebo 0.01 (−0.07, 0.09), I2 = 6%, 6 studies
Abbreviations: MCN, micronutrients; PZQ, praziquantel; STH, soil‐transmitted helminthiasis.
F IGURE 16 Weight gain (kg), aggregate level direct evidence for STH versus placebo. STH, soil‐transmitted helminthiasis
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for subgroup difference was not statistically significant (p = .25), with
an effect on height gain for studies for which we received data of
0.04 cm (95% CI: −0.04, 0.12) compared to an effect of 0.24 cm (95%
CI: −0.01, 0.30). The pooled effect on height gain across these 28
studies for STH deworming versus placebo was 0.09 cm (95% CI:
0.01, 0.17). This analysis included four studies of SAT (Sarkar, Anwar,
Biswas, & Mannan, 2002; Simeon et al., 1995; Tee, Lee, Noorizan,
Noori, & Raj, 2013; Yap et al., 2014) since we decided to include
these studies since our model adjusts for infection intensity. In this
aggregate level analysis, there is no adjustment for infection
intensity.
5.11.3 | Haemoglobin
Haemoglobin base case analyses
The effect of STH deworming alone versus placebo was 0.32 g/L
(95% CI: −0.63, 1.26) (Figure 18). Deworming for schistosomiasis
with or without STH deworming increased haemoglobin by 1.85 g/L
(95% CI: 0.53, 3.18) versus placebo. Deworming for schistosomiais
with or without STH deworming and micronutrients or iron increased
haemoglobin by 2.72 g/L (95% CI: 1.05, 4.40) compared to placebo.
Deworming for STH combined with iron and/or micronutrients
increased haemoglobin by 1.98 g/L (95% CI: 0.74, 3.21) compared to
placebo. The effect of micronutrients and/or iron versus placebo was
1.28 g/L (95% CI: 0.07, 2.49). This latter effect must be interpreted
with caution since there are many other studies of micronutrient and
iron supplementation in children that are not included in this review.
Direct evidenceaggregate and IPD
When comparing the three effect sizes of aggregate direct evidence,
IPD direct evidence and IPD‐NMA direct and indirect evidence, we
show the results below for the STH versus placebo and STH +
micronutrients/iron comparisons to placebo, showing similar size and
direction of effects for both comparisons (Table 15).
Analysis of the direct evidence of aggregate data from studies
confirmed heterogeneity <75% for all comparisons (Appendix 3).
Sensitivity analyses
All sensitivity analyses were congruent with these main findings
including the complete case model (14 studies, six nodes, unad-
justed), complete case with additional five studies (unadjusted) and
the unadjusted 14 study model (Table 16).
Analysis of the six studies with greatest impact on A. lumbricoides
prevalence at endline (relative risk of 0.80 or greater when compared
F IGURE 17 Height gain (cm), base
case, collapsed network, adjusted for
covariates
TABLE 12 Comparison of direct and indirect estimates for STH
versus placebo for height gain
Analysis
Effect estimate of STH vs.
placebo, height (cm)
Aggregate‐direct adjusted 0.04 (−0.04, 0.11), I2 = 11%
IPD‐direct adjusted 0.010 (−0.10, 0.30)
IPD‐NMA‐direct + indirect evidence
(adjusted)
0.09 (−0.08, 0.27)
Abbreviation: IPD, individual participant data; NMA, network
meta‐analysis; STH, soil‐transmitted helminthiasis.
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to placebo) found an effect of 2.74 g/L (95% CI: 0.95, 4.52) of STH
deworming with micronutrients or iron compared to placebo.
Comparison of effect sizes for haemoglobin (g/L) between received
data and studies that did not provide data
We assessed whether the effects on haemoglobin were similar for
these studies which did not provide data (either because they did not
provide it or because they did not meet eligibility criteria) to the
studies which did provide data (Appendix 3). The test for interaction
for subgroup differences for STH deworming versus placebo was not
statistically significant (p = .33). The effect size was 0.05 g/L (95% CI:
−0.02, 0.11) compared to an effect size of studies for which data was
not received of 0.00 (95% CI: −0.05, 0.06). Also, when sorted by year
of publication, there was no pattern in effect size based on the year
in which the study was published.
5.11.4 | Cognition
Six studies provided IPD data on cognition outcomes (Ebenezer et al.,
2013; Liu et al., 2017; Nga et al., 2009; Rohner et al., 2010;
Solon et al., 2003; Stoltzfus et al., 2004). These were analysed
separately for each study.
The baseline means and range of minimum and maximum scores
at baseline are given below to aid in interpreting the effect sizes
observed (Table 17).
Nga et al. (2009) found that digit forward was 0.38 (95% CI: 0.06,
0.71) units higher for albendazole + fortified biscuit compared to
unfortified biscuit, and that digit forward was also improved for
fortified biscuit alone compared to unfortified biscuit (0.57, 95% CI:
0.25, 0.88). All other outcomes had nonsignificant effects (see Table 18).
5.12 | Effect modifier analyses
We conducted subgroup analyses across each of the nine factors that
were deemed important by our advisory group.
There were insufficient numbers of children with moderate and
high intensity infections (as defined using the WHO cut‐offs) to run
the NMA model. Thus, we decided with our advisory board to use
three categories based on the distribution to assess whether there is
a gradient in effect across infection intensity. Light and moderate
infection intensity cutoffs were defined by the median infection
intensity in children who were infected across the whole population
of children in all 14 studies in the base case.
To further assess whether there was a gradient in effect size
across infection intensity, we conducted subgroup analysis for the
comparison with the most available data (STH deworming vs.
placebo). In this comparison of direct evidence from trials, 15% of
children had moderate or heavy infections according to WHO cut‐
offs for ascaris, T. trichiura and hookworm.
5.12.1 | BMI for age as effect modifier
Weight
Tests for interaction across BMI for age were not statistically
significant for weight gain across any comparison (Figures S13 and
Table S18).
Height
Tests for interaction were not statistically significant across BMI for
age for height gain in cm for any comparison (Figure S14; Tables S15
and S18).
Haemoglobin
There were no statistically significant subgroup differences across
BMI for age for change in haemoglobin for any comparison (Figure
S15 and Table S15).
Cognition
The test for interaction was not statistically significant across BMI
for age for cognition for any comparison (Table S16).
TABLE 13 Direct evidence, assessment of heterogeneity for height gain
Comparisons Effect estimate and heterogeneity of direct evidence (pooled at aggregate level)
STH deworming vs. placebo 0.05 (−0.02, 0.11), I2 = 11%, 9 studies
PZQ alone or with STH vs. placebo 0.04 (−0.12, 0.20) I2 = 0%, 5 studies
PZQ with MCN/iron vs. placebo 0.13 (−0.28, 0.54), I2 = 67%, 3 studies
STH deworming with MCN/iron vs. placebo 0.00 (−0.07, 0.08), I2 = 0%, 5 studies
MCN/iron vs. placebo 0.01 (−0.07, 0.09), I2 = 6%, 6 studies
Abbreviation: MCN, micronutrients; PZQ, praziquantel; STH, soil‐transmitted helminthiasis.
TABLE 14 Sensitivity analyses for STH versus placebo
Sensitivity analysis STH vs. placebo
Base case 0.09 (−0.08,0.27)
Unadjusted analyses 0.09 (−0.08,0.27)
Complete case (unadjusted), 14
studies
0.06 (−0.24,0.35)
Studies at low risk of bias, 0.11 (−0.11,0.33)
Full model with 18 nodes, 14
studies
Albendazole 2/year vs. placebo:
0.09 (−0.09,0.28)
Mebendazole 2/year vs. placebo:
0.13 (−1.47,1.74)
Complete case with additional
five studies
0.06 (−0.19,0.31)
Abbreviation: STH, soil‐transmitted helminthiasis.
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5.12.2 | Height for age‐as effect modifier
Weight
The test for interaction was not statistically significant across levels
of height for age for weight gain for any comparison (Figure S16 and
Table S18).
Height
The test for interaction was not statistically significant across levels
of height for age for height gain for any comparison (Figure S17 and
Table S18).
Haemoglobin
The test for interaction was not statistically significant across levels
of height for age for change in haemoglobin for any comparison
(Figure S18 and Table S18).
Cognition
When cognition for each of six studies (Ebenezer, Liu, Nga, Rohner,
Solon and Stoltzfus 2004) was analysed according to subgroups of
height for age of stunted (<−2 HAZ) or not stunted (≥−2.0 HAZ),
there were no statistically significant effects on cognition, except for
three comparisons. In these comparisons, albendazole combined with
fortified biscuits resulted in better improvement of −0.85 units on
digit forward (95% CI: −1.52, −0.18) compared to −0.20 (95% CI:
−0.57, 0.17) for children who were not stunteda. In the same study
(Nga), fortified biscuits resulted in improvement of digit forward of
−0.54 (9% CI: −0.90 to −0.18) for children with normal HAZ (>−2),
and similar improvement in stunted children (−0.78 digit forward
units, 95% CI: −1.42, −0.14) (Table S16).
5.12.3 | Sex, as an effect modifier
Weight
The test for interaction for subgroup effects was not statistically
significant across sex for weight gain for any comparison (Figure S19
and Table S16).
Height
The test for interaction for subgroup effects was not statistically
significant across sex for height gain for any comparison (Figure S20
and Table S16).
F IGURE 18 Change in haemoglobin
(g/L), base case collapsed network,
adjusted for covariates
TABLE 15 Direct and indirect evidence for haemoglobin STH
versus placebo
Analysis
Effect size STH
vs. placebo
STH+MCN/iron
vs. placebo
Direct‐aggregate 0.23 (−0.52, 0.97)
I2 0%
2.18 (1.02, 3.35),
I2 18%
Direct IPD 0.22 (−0.74,1.19) 1.76 (0.41,3.11)
IPD‐NMA direct
and indirect
0.32 (−0.63,1.26) 1.98 (0.74,3.21)
Abbreviation: IPD, individual participant data; MCN, micronutrients;
NMA, network meta‐analysis; STH, soil‐transmitted helminthiasis.
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Haemoglobin
The test for interaction for subgroup effects was not statistically
significant across sex for change in haemoglobin for any comparison
(Figure S21 and Table S16).
Cognition
Tests for interaction for subgroup effects across sex were not
statistically significant for cognition for any outcome measure or any
comparison (Table S16).
5.12.4 | Age, as effect modifier
Weight
Tests for interaction for subgroup effects across age were not
statistically significant for weight gain for any comparison (Figure
S22 and Table S16).
Height
The relatively small number of participants <5 years of age led to
wide CIs for estimates in this age group. Tests for interaction for
subgroup effects across age were not statistically significant for
height gain for any comparison (Figure S23 and Table S16).
Haemoglobin
Some comparisons did not have any children <5 years of age. Tests
for interaction for subgroup effects across age were not statistically
significant for change in haemoglobin for any comparison (Figure S24
and Table S16).
Cognition
Studies that reported cognition outcomes did not have children <5
years.
5.12.5 | A. lumbricoides, as effect modifier
We conducted two analyses because of the limited number of
children with moderate or heavy intensity infections:
1) NMA with IPD using cutoffs based on the distribution of intensity
in the sample of three levels, and
2) Direct evidence analysis with IPD using WHO cutoffs for intensity
of infection.
Weight
For the NMA‐IPD, tests for interaction for subgroup effects across A.
lumbricoides intensity were not statistically significant for weight gain
for the NMA. When using cut‐offs for intensity of infection for A.
lumbricoides based on the median distribution across three levels:
TABLE 16 Sensitivity analyses for haemoglobin
Sensitivity analysis STH vs. placebo STH+MCN/iron vs. placebo
Base case 0.32 (−0.63,1.26) 1.98 (0.74,3.21)
Unadjusted analyses 0.32 (−0.63,1.26) 1.98 (0.74,3.21)
Complete case (unadjusted), 14 studies 0.30 (−0.69,1.29) 3.18 (1.28,5.09)
Studies at low risk of bias, 0.07 (−1.05,1.19) 2.48 (0.57,4.39)
Full model with 18 nodes, 14 studies Albendazole 2/year: 0.16 (−0.86, 1.17)
Mebendazole 2/year: −0.10 (−6.61, 6.41)
Alben 2/year + foritifed beverage: 0.69 (−1.09, 2.48)
Meben 2/year+ iron: 2.73 (−0.06, 5.51)
Complete case with additional five studies 0.37 (−0.77,1.51) 1.83 (0.05,3.61)
Studies with greater impact on infection
prevalence
0.72 (−1.06,2.50) 2.74 (0.95,4.52)
Abbreviation: MCN, micronutrients; STH, soil‐transmitted helminthiasis.
TABLE 17 Baseline cognition measures for each study
Studies Outcome Mean Minimum Maximum
Ebenezer Single digit
attention score
12.2 0.0 20.0
Double digit
attention score
7.2 0.0 20.0
Math score 34.4 0.0 100.0
Tamil language
score
43.2 0.0 100.0
Liu Processing speed
index
86.2 45.0 138.0
Working memory
index
78.6 45.0 147.0
TIMSS z score 0.0 −2.4 2.1
Nga Raven score 16.4 0.0 35.0
Digit forward 7.0 2.0 9.0
Digit back 2.9 0.0 8.0
Block score 11.9 0.0 47.0
Code score 31.3 1.0 55.0
Stoltzfus04 Language skills 10.2 0.0 18.0
Motor skills 13.7 0.0 20.0
Solon Verbal ability 7.5 0.0 16.0
Quantitative ability 7.4 0.0 12.0
Nonverbal ability 2.7 0.0 7.0
Total cognition 17.6 2.0 34.0
Rohner Raven score 13.3 1.0 22.0
Coding total 18.0 3.0 43.0
Symbols total 8.6 1.0 20.0
Target marking
errors
0.1 0.0 8.0
Target marking time 45.5 20.0 105.0
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none detected, lighter intensity (1–1,776 epg), and higher intensity
(>1,776 epg), the effect for children with higher intensity was 0.08 kg
(95% CI: −0.13, 0.29) (Table S15).
For the analysis of STH deworming versus placebo using direct
evidence only for weight across three levels of A. lumbricoides
infection using WHO cutoffs: none detected, light (1–4,999 epg) and
moderate/heavy (≥5,000 epg), the interaction test for subgroup
effects was not statistically significant. The effects for children with
moderate or heavy intensity of A. lumbricoides infection was 0.12 kg
(−0.05, 0.28) which is higher than the effect for those with no
detected infection (−0.01 kg (95% CI: −0.11, 0.09) or those with light
infection intensity (0.04 kg, 95% CI: −0.07, 0.15) (Figure S25).
In order to explore the role of A. lumbricoides prevalence further,
we conducted a meta‐regression according to prevalence of A.
lumbricoides at the study level using aggregate data for all 30 studies
available with STH deworming versus placebo. We chose this
comparison since it is the comparison with the most data. The
results yielded a coefficient of 0.18 (SE, 0.24), p = .455, 95% CI:
−0.313, 0.68) with an adjusted R2 of −2.97% (proportion of between‐
study variance explained by prevalence of ascaris). These results
indicate that A. lumbricoides prevalence was not a significant
predictor of the effectiveness of deworming (Figure 19).
Height
Tests for interaction for subgroup effects across A. lumbricoides
intensity were not statistically significant for height gain for the
NMA. When using cut‐offs for intensity of infection for A.
lumbricoides based on the median distribution across three levels:
none detected, lighter intensity (1–1,776 epg), and higher intensity
(>1,776 epg), the effect modification for children with higher
intensity was 0.04 cm (95% CI: −0.22, 0.30) (Table S15).
For the posthoc direct evidence analysis of STH deworming
versus placebo for height gain across three levels of A. lumbricoides
infection, using WHO cutoffs: none detected, light (1–4,999 epg) and
moderate/heavy (≥5,000 epg), the interaction test for subgroup
effects was not statistically significant. The effect for children with
T
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moderate or heavy intensity of A. lumbricoides infection was 0.07 cm
(95% CI: −0.07, 0.22) (Figure S26).
Haemoglobin
Tests for interaction for subgroup effects across A. lumbricoides
intensity were not statistically significant for change in haemoglobin
for the NMA. When using cut‐offs for intensity of infection for A.
lumbricoides based on the median distribution across three levels:
none detected, lighter intensity (1–1,776 epg), and higher intensity
(>1,776 epg), the effect modification for children with higher
intensity was 0.48 g/L (95% CI: −0.69, 1.66) (Table S15).
For the posthoc analysis of direct evidence of STH deworming
versus placebo for haemoglobin across three levels of A. lumbricoides
infection, using WHO cutoffs: none detected, light (1–4,999 epg) and
moderate/heavy (≥5,000 epg), the interaction test for subgroup
effects was not statistically significant. The effect for children with
moderate or heavy intensity of A. lumbricoides infection was 0.44 g/L
(95% CI: −2.49, 1.60) (Figure S27).
Cognition
Tests for interaction for subgroup effects across A. lumbricoides
intensity were not statistically significant for single digit attention
scores, math scores, Tamil language scores, processing speed index,
working memory index, TIMSS z score, digit forward, digit back, block
score and code score (Table S16).
5.12.6 | Hookworm, as effect modifier
Two analyses were conducted: (a) NMA using cutoffs based on the
distribution of intensity in the sample of three levels and (b) direct
evidence analysis using WHO cutoffs for intensity of infection.
Weight
Tests for interaction for subgroup effects in the NMA across
hookworm intensity were not statistically significant for weight gain
for any comparison. When using cut‐offs for intensity of infection for
hookworm based on the median distribution across three levels:
none detected, lighter intensity (1–384 epg), and higher intensity
(>384 epg), the effect modification for children with higher intensity
was 0.16 kg (95% CI: −0.13, 0.46) (Table S15).
For the direct evidence, posthoc analysis using random effects
pairwise meta‐analysis of STH deworming versus placebo for weight
gain across three levels of hookworm infection using WHO cutoffs:
none detected, light (1–1,999 epg) and moderate/heavy (≥2,000 epg),
the interaction test for subgroup effects was not statistically
significant. The effect for children with moderate or heavy
intensity of hookworm infection was −0.53 kg (95% CI: −2.09, 1.03)
(Figure S28).
To further assess the role of prevelance of hookworm, we
conducted meta‐regression using aggregate level data for 23 studies
with data on hookworm prevalence for the comparison of STH
deworming versus placebo. The proportion of variance explained is
54%, p = .014, showing a positive relationship of weight gain with
hookworm infection prevalence (Figure 20).
Height
Tests for interaction for subgroup effects across hookworm intensity
were not statistically significant for height for any comparison in the
NMA. When using cut‐offs for intensity of infection for hookworm
based on the median distribution across three levels: none detected,
lighter intensity (1–384 epg), and higher intensity (>384 epg), the
effect modification for children with higher intensity was 0.20 cm
(95% CI: −0.13, 0.52) (Table S15).
For the direct evidence, posthoc analysis of STH deworming
versus placebo for height gain across three levels of hookworm
infection, using WHO cutoffs: none detected, light (1–1,999 epg) and
moderate/heavy (≥2,000 epg), the interaction test for subgroup
effects was not statistically significant. The effect for children with
moderate or heavy intensity of hookworm infection was −0.17 cm
(95% CI: −0.52, 0.18) (Figure S29).
Haemoglobin
Tests for interaction for subgroup effects across hookworm intensity
were not statistically significant for change in haemoglobin for any
comparison in the NMA. When using cut‐offs for intensity of
infection for hookworm based on the median distribution across
three levels: none detected, lighter intensity (1–384 epg) and higher
intensity (>384 epg), the effect modification for children with higher
intensity was 3.58 g/L (95% CI: 0.13, 7.02) (Table S15).
For the direct evidence, posthoc analysis of STH deworming
versus placebo for haemoglobin across three levels of hookworm
infection using WHO cutoffs: none detected, light (1–1,999 epg) and
moderate/heavy (≥2,000 epg), the interaction test for subgroup
effects was not statistically significant. The effect for children with
moderate or heavy intensity of hookworm infection was −0.56 g/L
(95% CI: −6.39, 5.27) (Figure S30).
F IGURE 20 Meta‐regression of hookworm prevalence at
aggregate level for 23 studies with data on STH versus placebo. STH,
soil‐transmitted helminthiasis
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Cognition
Tests for interaction for subgroup effects across hookworm intensity
were not statistically significant for any comparison for single digit
attention scores, math scores, Tamil language scores, processing
speed index, working memory index, TIMSS z score, digit forward,
digit back, block score and code score (Table S16).
5.12.7 | T. trichiura, as effect modifier
We conducted two analyses: (a) NMA using cutoffs based on the
distribution of intensity in the sample of three levels and (b) direct
evidence analysis using WHO cutoffs for intensity of infection.
Weight
Tests for interaction for subgroup effects across T. trichiura intensity
were not statistically significant for weight gain for any comparison in
the NMA. When using cut‐offs for intensity of infection for T. trichiura
based on the median distribution across three levels: none detected,
lighter intensity (1–288 epg), and higher intensity (>288 epg), the
effect modification for children with higher intensity was 0.17 kg
(95% CI: −0.06, 0.41) (Table S15).
For the direct evidence, posthoc analysis of STH deworming
versus placebo for weight gain across three levels of T. trichiura
infection using WHO cutoffs: none detected, light (1–999 epg) and
moderate/heavy (≥1,000 epg), the interaction test for subgroup
effects was not statistically significant. However, the effect for
children with moderate or heavy intensity of T. trichiura infection was
0.11 kg (−0.14, 0.35) which was higher than for those with no
detected infection (Figure S31).
Height
Tests for interaction for subgroup effects across T. trichiura intensity
were not statistically significant for height for any comparison in the
NMA models. When using cut‐offs for intensity of infection for T.
trichiura based on the median distribution across three levels: none
detected, lighter intensity (1–288 epg), and higher intensity (>288
epg), the effect modification for children with higher intensity was 0.
07 cm (−0.02, 0.34) (Table S15).
For the direct evidence, posthoc analysis of STH deworming
versus placebo for height gain across three levels of T. trichiura
infection using WHO cutoffs: none detected, light (1–999 epg) and
moderate/heavy (≥1,000 epg), the interaction test for subgroup
effects was not statistically significant. The effect for children with
moderate or heavy intensity of T. trichiura infection was −0.17 cm
(−0.52, 0.18) (Figure S32).
Haemoglobin
Tests for interaction for subgroup effects across T. trichiura intensity
were not statistically significant for haemoglobin for any compar-
isonmin the NMA models. When using cut‐offs for intensity of
infection for T. trichiura based on the median distribution across
three levels: none detected, lighter intensity (1–288 epg), and higher
intensity (>288 epg), the effect modification for children with higher
intensity was 1.33 g/L (−1.14, 3.81) (Table S15).
For the direct evidence, posthoc analysis of STH deworming
versus placebo for change in haemoglobin across three levels of T.
trichiura infection using WHO cutoffs: none detected, light (1–999
epg) and moderate/heavy (≥1,000 epg), the interaction test for
subgroup effects was not statistically significant. The effect for
children with moderate or heavy intensity of T. trichiura infection was
0.33 g/L (−2.99, 3.65) (Figure S33).
Cognition
Tests for interaction for subgroup effects across T. trichiura intensity
were not statistically significant for any comparison for single digit
attention scores, math scores, Tamil language scores, processing
speed index, working memory index, TIMSS z score, digit forward,
digit back, block score and code score (Table S16).
5.12.8 | Any helminth infection, as effect modifier
Weight
Tests for interaction for subgroup effects across a composite
category of intensity of infection for any parasite were not
statistically significant for weight gain for any comparison in the
NMA‐IPD model (Figure S34 and Table S15).
Height
Tests for interaction for subgroup effects across a composite
category of intensity of infection for any parasite were not
statistically significant for height gain for any comparison (Figure
S35and Table S15).
Haemoglobin
Tests for interaction for subgroup effects across a composite
category of intensity of infection for any parasite were not
statistically significant for change in haemoglobin for any comparison
(Figure S36and Table S15).
Cognition
Tests for interaction for subgroup effects across a composite
category of intensity of infection for any parasite were not
statistically significant for any comparison for single digit attention
scores, math scores, Tamil language scores, processing speed index,
working memory index, TIMSS z score, digit forward, digit back, block
score and code score (Table S16).
5.12.9 | Anaemia as an effect modifier
Weight
Tests for interaction for subgroup effects across anaemia were not
statistically significant for weight gain for any comparison (Figure
S37 and Table S15).
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Height
Tests for interaction for subgroup effects across anaemia were not
statistically significant for height gain for any comparison (Figure 38
and Table S15).
Haemoglobin
Tests for interaction for subgroup effects across anaemia were not
statistically significant for change in haemoglobin for any comparison
(Table S15; Figures 21 and S39).
Cognition
Tests for interaction for subgroup effects across anaemia were not
statistically significant for any comparison for single digit attention
scores, math scores, Tamil language scores, working memory index,
TIMSS z score, digit forward, digit back, block score and code score
(Table S16).
5.12.10 | Year of publication
We planned to restrict our IPD‐NMA to studies conducted 2008 or
later. However, we decided that it would be more informative to
conduct a meta‐regression using aggregate data according to year of
publication to include older studies for which we were unable to
obtain individual participant datasets.
This analysis shows a negative association, with a greater effect
in older studies which was not statistically significant (p = .05) and
explained 7.88% of the variance between studies. The graph shows a
concentration of more recent studies with smaller effects on weight
gain.
5.13 | Comparison with other recent systematic
reviews for STH deworming versus placebo
We compared our findings for weight gain, height gain and
haemoglobin and cognition to a Cochrane review (Taylor‐Robin-
son et al., 2015) and prior Campbell review, which both used
aggregate level data (Table 19).
Also, the Welch et al. 2016 review assessed the relationship of
aggregate data with prevalence of each type of helminth infection,
and found no relationship using two different methods. The findings
of this systematic review and IPD‐NMA are in agreement with this,
using IPD‐NMA effect modification tests for subgroup effects, and
aggregate data subgroup analysis as well as meta‐regression across
prevalence of ascaris. Unlike our prior systematic review, we did find
a statistically significant relationship with hookworm prevalence and
effect on weight gain.
We also compared our findings to Croke et al. meta‐analysis
(Croke et al., 2016; Table 20). This comparison contains 34 possible
effect estimates from 33 studies of STH deworming versus placebo.
The meta‐analysis by Croke et al. does not include 13 estimates
which we have included, two because they are SAT studies (Sarkar
et al., 2002; Yap et al. 2014). The remaining studies, it is unclear why
they were excluded since no table of excluded studies is provided.
F IGURE 21 Metaregression according to year of publication for
difference in weight gain (kg)
TABLE 19 Comparison of results with other recent systematic reviews and meta‐analyses
Review
Taylor‐Robinson et al. (2015),
Regular frequency STH
deworming (2/year) vs.
placebo
Welch et al. (2016), Albendazole 2/year
vs. placebo
Welch et al. (2018) STH deworming vs.
placebo
Weight gain 0.08 kg (95% CI: −0.11, 0.27) 0.09 kg (95% CI: −0.04, 0.2), IPD‐NMA: 0.01 kg (95% CI: −0.08, 0.11)
Aggregate level, all studies (received, not
received and ineligible due to lack of baseline
infection intensity: 0.07 (95% CI: 0.01, 0.13)
random effects
Height gain 0.02 cm (95% CI: −0.14, 0.17) 0.07 cm (95% CI: −0.1, 0.24 cm), 0.09 cm (95% CI: −0.08, 0.27)
Change in
haemoglobin
0.02 g/dl, (95% CI: −0.08, 0.04) Not pooled, concluded there were
effects only when combined with
micronutrients, iron or praziquantel
0.32 g/L (95% CI: −0.63, 1.26).
Cognition Little to no effect 0.23 points on a 100 point scale (95% CI:
−0.6, 0.14)
Little to no effect
Abbreviation: IPD, individual participant data.
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We excluded four studies where STH was combined with micro-
nutrients or iron and compared to micronutrients or iron. This is
because of our decision to keep this as a separate treatment
comparison. The table below shows that our effect estimate is lower
than Croke et al. for both fixed and random effects. Even when we
conduct a sensitivity analysis, adding the four studies of STH +
micronutrients versus micronutrients, we still have a lower effect
estimate than Croke et al. (2016) with a random effects meta‐
analysis of 0.10 kg (95% CI: 0.03, 0.17) and fixed effects 0.07 (95%
CI: 0.04, 0.10).
Our primary analysis was deworming versus placebo (without
cointerventions) because it was the closest match to our NMA.
5.13.1 | Notes for those with different point
estimates and standard errors
Awasthi and Pande (2001): We used 1 year data reported in
Taylor‐Robinson, Maayan, Soares‐Weiser, Donegan, and Garner
(2012) systematic review. Croke et al. (2016) used 2 year data.
Donnen et al. (1998): we used adjusted estimates reported by
Donnen et al. (1998). Croke et al. (2016) used unadjusted estimates
provided to the Cochrane authors.
Kruger et al. (1996): Kruger et al. (1996) randomised children to
anthelminthic therapy (albendazole 400mg once at baseline and
once 5 months later) versus placebo tablets. In addition, three
schools received fortified soup and two received unfortified soup.
Taylor‐Robinson et al. (2015) and Croke et al. (2016) evaluated the
effect of anthelminthics for the children who did not receive fortified
soup to avoid the confounding effect of iron (n = 74). Since we
considered that the fortified soup and unfortified soup were not
randomised, we collapsed across the fortified and unfortified soup
conditions, calculating an overall effect for all children randomised to
anthelminthics versus placebo (n = 178).
Liu et al. (2017): We used IPD data provided by the authors.
Croke et al. (2016) used published mean changes.
Miguel and Kremer (2004): We used data from the public use
files for the 1st year of comparison, where we considered Group 1 as
STH deworming and Groups 2 and 3 as control. It is not clear which
data were used by Croke et al., but they may have had access to
different datasets, or used data from the 2nd year of the study.
Ndibazza et al. (2012): We used data from IPD provided by the
authors. Croke et al. used mean changes provided by the authors to
Welch et al. for the 2016 review.
Wiria et al. (2013): Croke et al. (2016) used a table provided by
the authors with baseline weight, and weight at 9 and 21 months,
then calculated a change score and associated variance. We were
able to replicate this table from the authors. However, we used IPD
change score for children with complete data at baseline and 9
months to calculate a change score.
Studies not included in Welch et al. analysis: We did not include
four studies in this analysis since they are a comparison of
deworming combined with vitamin A versus vitamin A (Awasthi
et al., 2008; Awasthi & Pande, 2001; Hall et al., 2006) or STHT
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deworming + iron versus iron (Dossa et al., 2001). Because we used a
NMA approach, these studies are included in the node for STH +
micronutrients or iron compared to micronutrients or iron. In a
sensitivity analysis, we included these studies to assess the influence
on our results, and our random effects meta‐analysis was 0.10 kg
(95% CI: 0.03, 0.17). Note: these studies are included in the NMA‐
IPD presented in this paper if they had baseline infection intensity
and provided data (that is, Hall et al. (2006) was included).
6 | DISCUSSION
6.1 | Summary of main results
This IPD NMA and systematic review reinforces findings from
previous meta‐analyses and the 2017 WHO guidelines on mass
deworming that STH deworming alone is insufficient to improve
population level child health and cognitive outcomes based on
moderate certainty evidence. When we add data obtained for this
IPD analysis from unpublished results on weight gain to studies
included in our prior meta‐analysis, the overall effect across 25
studies of deworming compared to placebo is 0.07 kg (−0.01, 0.13).
This effect size is comparable to other published systematic reviews
and meta‐analyses.
A central issue in deworming debates has been the difficulty of
detecting effects when the majority of the population has light or no
detectable infection. Our review is unique in its ability to assess
effect modification using IPD. Effect modification analyses across
intensity of infection, using WHO cutoffs, suggest that deworming
may slightly increase weight in children with moderate to heavy
intensity infections of A. lumbricoides or T. trichiura (very low
certainty).
At the population level, for weight gain, we found little effect for
STH deworming versus placebo with our NMA IPD results (0.01 kg;
95% CI: −0.08, 0.11) with moderate quality evidence, and results for
all other comparisons were similar. For height, we found little effect
on height (0.09 cm; 95% CI: −0.08, 0.27) with moderate quality
evidence and similar effects across all comparisons. For haemoglobin,
we found little effect of deworming for STH (0.32, 95% CI: −0.63,
1.26) (low certainty). Deworming with praziquantel resulted in an
increase in haemoglobin compared to placebo of 1.85 g/L (95% CI:
0.53, 3.18). Similarly, deworming with praziquantel combined with
iron or micronutrients increased haemoglobin (2.72 g/L, (95% CI:
1.05, 4.40), iron or micronutrients with STH deworming increased
haemoglobin (1.98 g/L, (95% CI: 0.74, 3.21) compared to placebo (low
certainty evidence). For cognition, studies reported no effects of any
types of deworming on short term attention measures such as digit
forward or processing speed or measures of child development.
Subgroup analysis were considered at very low certainty due to
imprecision of results. There were no statistically significant
subgroup effects across age, sex, infection intensity for any type of
STH infection using median distribution of intensity, BMI for age,
height for age or anaemia (moderate certainty). For subgroup
analysis using WHO cutoffs and direct evidence, children with
moderate to heavy A. lumbricoides or hookworm infection, deworm-
ing may slightly increase weight but not height or haemoglobin
compared to children with no detected infection or light infection
intensity (very low certainty evidence).
These findings were robust to sensitivity analyses across risk of
bias and effectiveness of studies at reducing infection prevalence as
well as differences in the model structure, adjustment for covariates,
risk of bias and the use of multiple imputation for missing data.
Clinical importance of weight and height for STH deworming
needs to be put in the context of the children in these studies, where
33% of children were stunted, 54% were anaemic, 41% were infected
with hookworm, 48% with A. lumbricoides, 53% with trichuris and
73% were over 5 years of age. According to WHO growth standards,
weight gain for children aged 7 years is approximately 2 kg in 12
months. Therefore, the 95% CI observed in our analysis of −0.08 to
0.11 kg for STH versus placebo is equivalent to −4% to +5.5% relative
to the expected weight gain over this time period for these children.
This is much smaller than effects of other nutritional programmes
such as schoolfeeding which increases weight gain by about 0.39 kg
annually (Kristjansson et al., 2007). We are moderately certain that
further research will not change this estimate. Uncertainty arises
since we were unable to obtain data from all published trials.
Clinical importance of haemoglobin effects need also to be
considered in light of the average haemoglobin level of these
children, and the settings in which they live. Almost half (46%) of our
sample was anaemic, defined as haemoglobin below 115 g/L. STH
deworming alone compared to placebo had small effects on
haemoglobin (0.32 g/L) but STH deworming combined with micro-
nutrients or iron compared to placebo had larger effects (1.98 g/L). as
a comparison, iron supplementation alone for children <12 years of
age was found to increase haemoglobin by approximately 5 g/L (De‐
Regil et al., 2011).
We were successful in retrieving 14% (2/14 studies) for
deworming for schistosomiasis. As a result, we were unable to
conduct our planned analysis of deworming for schistosomiasis.
6.2 | Overall completeness and applicability of
evidence
For STH deworming, we received data for 19 studies with 31,945
participants of an eligible 41 studies with 40,132 participants for
studies of STH deworming. Fifteen of the 19 studies were published
in the last 15 years.
We had sufficient participants in each level of our planned effect
modifier analyses to run all of our planned effect modification
analyses using the base case evidence network. Although there were
no statistically significant differences across infection intensity levels,
these were limited due to the paucity of children with moderate to
heavy infection intensity in our sample (<13%). Furthermore, the
upper CIs included potentially important effects of up to 460 g for
weight and 7 g/L for haemoglobin. In direct evidence comparisons
using WHO cutoffs, we also did not find statistically significant
interaction across intensity of infection, however, there were larger
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effects on weight gain for children with moderate or heavy intensity
infections of A. lumbricoides or T. trichuria. For prevalence of A.
lumbricoides and hookworm, we also assessed whether there was a
relationship between prevalence and effects on weight using meta‐
regression for aggregate data for all studies with weight data for STH
deworming versus placebo. These analyses did not show a relation-
ship with A. lumbricoides prevalence at the study level. There was an
association of higher hookworm prevalence with effect on weight.
These meta‐regressions must be interpreted with caution since they
are using data at the aggregate level (Debray et al., 2018).
We conducted an extensive search of electronic databases, with
advice from the Campbell Collaboration International Development
Group information scientist. We screened 16,613 articles and
updated this search to March 27, 2018. We report the systematic
review according to the reporting guidelines for IPD meta‐analysis
(PRISMA‐IPD) and network‐meta‐analysis (PRISMA NMA).
We published and followed an a priori protocol (Welch et al.,
2018). Our systematic review and IPD analysis was approved by the
Research Ethics Boards at SickKids and Bruyere Research Institute.
We developed a data sharing agreement that was signed by all
studies that contributed data. Study authors were invited to join the
Investigators’ Collaborative, participate in meetings and contribute
to the final report. Our process to developing the evidence network
was driven by consultation with our expert Advisory board which
included statistical, parasitology and nutrition expertise. We tested
our assumptions, model structure and statistical methods using
sensitivity analyses.
The studies were conducted in a range of low and middle income
countries in settings with predominantly poor sanitation with a range
of prevalence of STH in children aged from 6 months to 17 years. The
prevalence of A. lumbricoides infections in our base case sample (14
studies with sufficient data for multiple imputation) was 52% (range,
9–93%), hookworm 45% (range, 1–94%) and T. trichiura 52% (range,
9–96%). Less than 15% of children had an infection intensity
considered moderate or heavy for A. lumbricoides, T. trichiura or
hookworm, according to the WHO criteria in our sample. Our dataset
included 2,448 children <5 years of age in our main models (18% of
the sample).
Our data suggest that there is publication bias in the deworming
literature with failure to report growth data since we obtained
weight and height data from eight studies which had not previously
reported these (Beasley et al., 1999; Beasley, 1995; Friis et al., 2003;
Ebenezer et al., 2013; Kirwan et al., 2009; Le Huong et al., 2007;
Rohner et al., 2010; Solon et al., 2003). We also report cognition data
that was not previously published from one study (Rohner et al.,
2010). Given our findings of selective outcome reporting, it is still
possible that there are additional older studies with negative
findings.
We compared the effect sizes observed in the studies that we
retrieved to those which were excluded (due to missing baseline
infection intensity) or which we were unable to obtain from the trial
authors (due to lost datasets, administrative hurdles or nonresponse
from the authors). We found that the test for interaction for
subgroup differences was not statistically significant for weight,
height or haemoglobin, but the effect on weight was higher in the
studies which were not obtained, which were mostly older studies.
For schistosomiasis deworming, we received only two of 14
eligible studies. We decided that meta‐analysis of these two studies
would be misleading and did not pursue IPD meta‐analysis for
schistosomiasis deworming. We did include nodes in our evidence
network for combinations of schistosomiasis deworming and STH
deworming, but these had relatively fewer studies and participants.
Small amounts of calories were provided in three studies in the
form of unfortified or fortified biscuits (Nga et al., 2009), noodles (Le
Huong et al., 2007) or beverage (Solon et al., 2003). In each of these
studies, the comparator groups received the unfortified food or
beverage. We did not identify any studies that looked at providing
substantive meals or snacks with deworming. Thus, we cannot draw
conclusions on the effects of deworming when combined with
feeding programmes in comparison to not providing feeding.
6.3 | Quality of the evidence
We included only RCTs. About 40% of trials did not provide enough
information to assess adequacy of randomisation and allocation
concealment. We considered the included studies were at overall low
risk of bias. The quality of evidence as assessed using the GRADE
framework was moderate across all outcomes and comparisons for
the main effects. Quality of evidence was downgraded because of
uncertainty about selective reporting bias across the evidence base,
and the fact that we were not able to obtain data from all eligible
studies. Subgroup effect analyses were judged at very low certainty
due to imprecision and inability to obtain all eligible studies.
Sensitivity analyses across adequacy of allocation concealment
were congruent with our main findings for weight, height and
haemoglobin for all comparisons.
6.4 | Limitations and potential biases in the review
process
One limitation of this review is that we did not receive data from all
eligible studies. We compared published results of the studies
received for STH deworming versus placebo with the studies that
were not received and those that were not eligible to assess the
potential influence of these missing studies on our findings. The test
for interaction was not statistically significant but the effect on
weight gain overall was larger in studies that were not received,
which limits the ability of this analysis to assess the overall,
population level effects. However, this should not affect the effect
modification analyses since these are based on individual level
covariates. There was no trend in effect size or direction across the
year of publication for weight, height or haemoglobin.
The assumptions of transitivity and consistency were assessed
and considered plausible by assessing distribution of effect modifiers,
assessing within comparison heterogeneity in direct evidence and by
comparing direct and indirect evidence.
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Another limitation is that different diagnostic tools with different
measuring properties including Kato‐Katz, polymerase chain reaction
(PCR) and other techniques, were used for assessing infection
intensity across the studies and may lead to measurement error.
Only one study used PCR, and we used its infection intensity
estimates in analyses with other studies, recognising that there may
be differences in sensitivity of these tests.
Cognitive outcomes are measured using diverse tools and some
are translated for use in these studies. For this reason we presented
each cognitive outcome for each study separately without combining
them in a meta‐analysis. This limits the ability to combine results
across studies thus these analyses are under‐powered for cognitive
outcomes.
We were unable to assess effect modification for infection
intensity using the WHO cutoffs for moderate or heavy intensity
using our NMA model because <15% of children in our sample met
criteria for being moderately to heavily infected, thus the models
failed to converge when we used the WHO cutoffs for moderate and
heavy intensity infection. To further investigate the importance of
infection intensity, we conducted subgroup analysis using the WHO
cutoffs for each infection type (none detected, light and moderate/
heavy) for the direct evidence of STH deworming versus placebo. The
test for interaction for subgroup effects across infection intensity for
STH deworming versus placebo for weight, height or haemoglobin
was not statistically significant. However, the effect of deworming
was higher for weight gain for children with moderate/heavy
infection of A. lumbricoides and T. trichuria, compared to children
with light intensity infections or no detected infection. These
subgroup analyses were considered very low certainty evidence
due to imprecision.
The study durations were short with a median duration of 12
months (ranging from 4 to 45 months) and this may have limited our
ability to detect changes in height or weight gain. However, since two
of the earlier studies mentioned previously with large effects on
weight (Stephenson et al., 1989, 1993) were only 6 and 8 months in
duration, we consider that the study durations of these studies was
sufficient to assess differences in weight gain. It is unlikely that these
study durations are sufficient to assess differences in linear growth.
Single dose trials of short duration may not be able to detect positive
effects due to high re‐infection rates in endemic areas.
In our collapsed model, we collapsed across frequency of
deworming which limits our ability to assess whether high frequency
STH deworming is more effective than regular frequency deworming.
As described above, our preliminary models with frequency of
administration as separate nodes did not show differences in effects
on weight, height or haemoglobin between high frequency and
regular frequency deworming.
Two studies in Kenya have shown large effects on weight gain of
1 kg or more (Stephenson et al., 1989, 1993). The reason for these
large effects is unclear. Analysis of heterogeneity led us to exclude
the Stephenson et al. (1989) study due to baseline imbalance in a
prior systematic review (Welch et al., 2016). The conditions in which
those two trials were carried out may have been different from other
trials, including characteristics such as intensity of infection,
sanitation, and participant and investigator adherence to protocols.
However, 25 other studies are available on STH versus placebo, and
when all are combined, the overall effect in our analyses is 70 g.
The older studies of deworming suggested stronger effects on
nutrition and other health outcomes than we have found in our
analysis. Given that stunting is associated with adverse health and
cognitive outcomes that implied (since deworming drugs are
inexpensive) that deworming is cost‐effective. However, our study
would cast doubt on this, since at moderate levels of infection, we
could not discern significant impacts on key nutrition outcomes such
as stunting and wasting. Our systematic review cannot predict
outcomes and cost‐effectiveness for chemoprophylaxis where infec-
tion is severe, since we had <2% of our sample with heavy intensity
infections.
Our study did not look at school attendance which has been used
for previous cost‐effectiveness analysis of deworming. There has
been an intense debate on this topic where an independent
replication identified smaller benefits than previously thought (Aiken,
Davey, Hargreaves, & Hayes, 2015; Hargreaves, Aiken, Davey, &
Hayes, 2015; Hicks, Kremer, & Miguel, 2015). Also, our prior
systematic review found an average effect on school attendance of
1% (95% CI: −1, 3%) (Welch et al., 2016). We also identified problems
with the methods of measuring school attendance in these studies.
The implication is that the cost‐effectiveness/cost benefit of
deworming on the basis of school attendance is not proven.
The exclusion of studies with <100 participants may lead to small
study bias. However, only three studies had <100 participants;
including them would not affect the main analyses or effect
modification analyses.
6.5 | Agreements and disagreements with other
studies or reviews
A Cochrane review (Taylor‐Robinson et al., 2015) and Campbell
review (Welch et al., 2016) on mass deworming for children both
concluded there was little to no effect on weight and height for STH
deworming. The effects observed in Taylor‐Robinson et al. (2015)
were a mean difference of 0.08 kg (95% CI: −0.11, 0.27) on weight, a
mean difference of 0.02 cm (95% CI: −0.14, 0.17) on height and a
mean difference of 0.02 g/dL, 95% CI: −0.08, 0.04) on haemoglobin
for regular treatment, and little to no effect on formal tests of
cognition (Taylor‐Robinson et al., 2015). In Welch et al. (2016), the
effects of Albendazole twice per year were 0.09 kg (9%CI: −0.04, 0.2),
0.07 cm (95% CI: −0.1, 0.24 cm), short term cognition −0.23 points on
a 100 point scale (95% CI: −0.6, 0.14). Haemoglobin effects were not
combined across studies in Welch et al., but the individual study
results are consistent with our finding that there are robust effects
on haemoglobin only when iron, micronutrients or praziquantel are
combined with STH deworming.
Our findings for STH deworming versus placebo for height,
cognition and haemoglobin are similar to these two prior reviews.
Our IPD‐NMA effect on weight gain of 0.01 kg (95% CI: −0.08, 0.11)
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is lower than these reviews, and is likely due to not being able to
retrieve data from all eligible studies. Our meta‐regression of year of
publication and weight gain did not show a statistically significant
effect of year of publication, but this must be interpreted with
caution since metaregression suffers from low power and was based
on aggregate data. The smaller effect seen in our analysis may be
related to publication bias in the previous reviews since we obtained
unpublished data which is known to be associated with negative
findings (defined as smaller effects or nonstatistically significant;
Hopewell, Loudon, Clarke, Oxman, & Dickersin, 2009) and that we
did not receive data from all available studies.
Our finding on weight gain with our IPD‐NMA of 0.01 kg is
considerably smaller than in the meta‐analysis by Croke et al. (2016)
on weight gain (http://www.nber.org/papers/w22382.pdf), which
found an average overall effect on weight gain of 0.134 kg (95% CI:
0.031, 0.236). When comparing our analyses of direct evidence from
all studies with STH deworming versus placebo (including both
studies for which we received IPD and studies which did not
contribute IPD), we also found a smaller effect size than Croke et al.
of 0.07 kg (95% CI: 0.01, 0.13) on weight with random effects. Our
finding that there were no subgroup effects across infection intensity
or association of effect size with prevalence do not agree with Croke
et al.’s findings that the effect on weight was higher for studies with
>20% prevalence (0.148 kg, 95% CI: 0.039, 0.2225558). Much of the
difference in our findings across prevalence and intensity of infection
may be due to the fact that NMA‐IPD has better power to detect
subgroup differences than aggregate level subgroup analyses or
meta‐regression (Dagne et al., 2016).
7 | AUTHORS ’ CONCLUSIONS
7.1 | Implications for policy
The policy implications are that deworming alone is insufficient to
achieve improvements in population‐level growth, nutritional status
and cognition. Based on the totality of evidence from three prior
systematic reviews and new data from IPD previously unpublished,
average effects of mass deworming on child nutritional status and
cognition are small at the population level (moderate certainty).
Effects are higher for children with moderate to heavy intensity
infections thus mass deworming may be beneficial in areas with
heavy intensity infections. In areas with predominantly lighter
infections, effects are smaller thus policymakers and programmers
need to explore other policy options to improve child health and
nutrition in these areas.
7.2 | Implications for research
IPD analyses such as this have greater power to investigate effect
modifiers, but are currently limited by the time and resources needed
to seek data from all eligible studies and the limited availability of
such data. There is an urgent need for open data from all research
studies. Our analyses were limited by obtaining only 46% of eligible
studies, mostly conducted in the last 15 years, which could be
mitigated by having all data from prospectively registered trials
available in open data repositories, as called for by the Alltrials
campaign.
The quality of evidence is rated as moderate for our findings,
mainly due to the possibility of selective reporting and publication
bias in the body of literature. Further research to obtain additional
unpublished data on growth and cognition could change our findings.
For schistosomiasis deworming, we were unable to obtain the
majority of studies, thus we did not carry out these analyses.
Further short‐term studies of STH deworming in lightly infected
populations are not likely to change the certainty or sizes of effects
observed in this systematic review or in other systematic reviews of
deworming.
Ideally, in the design of studies, duplicate methods to measure
exposure and outcome in a reliable way would be important. For
example, future studies could use more sensitive diagnostic tools
(e.g., PCR). Also, for cognition, proper cultural translations and
validation of measurement tools are important.
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